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Abstract
Background: An estimated two-thirds of the world's 3.2 million stillbirths occur antenatally, prior to
labour, and are often overlooked in policy and programs. Poorly recognised, untreated or inadequately
treated maternal infections such as syphilis and malaria, and maternal conditions including hypertensive
disorders, are known risk factors for stillbirth.
Methods: We undertook a systematic review of the evidence for 16 antenatal interventions with the
potential to prevent stillbirths. We searched a range of sources including PubMed and the Cochrane
Library. For interventions with prior Cochrane reviews, we conducted additional meta-analyses including
eligible newer randomised controlled trials following the Cochrane protocol. We focused on interventions
deliverable at the community level in low-/middle-income countries, where the burden of stillbirths is
greatest.
Results:  Few of the studies we included reported stillbirth as an outcome; most that did were
underpowered to assess this outcome. While Cochrane reviews or meta-analyses were available for many
interventions, few focused on stillbirth or perinatal mortality as outcomes, and evidence was frequently
conflicting. Several interventions showed clear evidence of impact on stillbirths, including heparin therapy
for certain maternal indications; syphilis screening and treatment; and insecticide-treated bed nets for
prevention of malaria. Other interventions, such as management of obstetric intrahepatic cholestasis,
maternal anti-helminthic treatment, and intermittent preventive treatment of malaria, showed promising
impact on stillbirth rates but require confirmatory studies. Several interventions reduced known risk
factors for stillbirth (e.g., anti-hypertensive drugs for chronic hypertension), yet failed to show statistically
significant impact on stillbirth or perinatal mortality rates. Periodontal disease emerged as a clear risk factor
for stillbirth but no interventions have reduced stillbirth rates.
Conclusion: Evidence for some newly recognised risk factors for stillbirth, including periodontal disease,
suggests the need for large, appropriately designed randomised trials to test whether intervention can
minimise these risks and prevent stillbirths. Existing evidence strongly supports infection control measures,
including syphilis screening and treatment and malaria prophylaxis in endemic areas, for preventing
antepartum stillbirths. These interventions should be incorporated into antenatal care programs based on
attributable risks and burden of disease.
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Introduction
Of the world's 3.2 million annual stillbirths, at least 98%
occur in low-/middle-income countries, and on average,
as many as two-thirds of these stillbirths are thought to
occur antenatally, prior to labour [1,2]. Proportions of
antenatal and intrapartum stillbirths may vary in different
low- and middle-income country settings depending on
the prevalence of risk factors and quality of antenatal and
obstetric care. Antenatal stillbirths typically show signs of
maceration, and result from an insult occurring in utero
[3]. Interventions targeting this period can play a major
part in reducing the burden of stillbirths. Many known
causes of antenatal stillbirths, including infections and
maternal conditions including gestational diabetes and
hypertension, are potentially preventable or treatable; rel-
atively simple interventions may reduce their incidence.
Known risk factors include syphilis, ascending bacterial
vaginal infections, pre-existing and gestational maternal
conditions like diabetes, inherited thrombophilias, and
intrahepatic cholestasis; pre-eclampsia, placental abrup-
tion and other placental dysfunction; and maternal Rhe-
sus disease [4].
Interventions targeting these risk factors may reduce still-
birth rates, especially in low- and middle-income coun-
tries. However, the evidence for impact of these
interventions on stillbirth and perinatal mortality rates
has not been extensively reviewed. This paper systemati-
cally examines the evidence for interventions to address or
ameliorate the impact of known or biologically plausible
clinical risk factors for stillbirth that are treatable or pre-
ventable during the antenatal period. Many of the risk fac-
tors examined are more prevalent in low- and middle-
income countries than in high-income countries, includ-
ing infections such as syphilis and malaria. Lack of access
to health facilities providing antenatal care (ANC) or
emergency obstetric care, especially in rural or otherwise
remote areas, is associated with poor obstetric outcomes
[5,6]. Many of the interventions examined in this review
are deliverable via outreach services at the community
level, but some require equipped and functional facilities.
Methods
The methodology of the literature search, along with the
data analysis strategy, has been detailed previously [7].
We consulted PubMed and the Cochrane Library, includ-
ing all human studies published after 1980. We included
gray literature wherever possible. General search terms
were used like "stillbirth", "fetal death" and "perinatal
mortality", along with targeted terms like "antibiotics
AND pregnancy" and "periodontal AND pregnancy".
Interventions delivered during pregnancy for prevention
or treatment of maternal infections or conditions are ana-
lyzed in this paper for their effect on stillbirths or perina-
tal mortality as shown in Table 1.
A total of 345 papers (35 systematic reviews and 310 indi-
vidual studies) met the study criteria and were included in
this paper.
Results
Prevention and management of problems in 
pregnancy
Calcium supplementation to prevent pregnancy-induced 
hypertension (PIH) and pre-eclampsia
Background
High blood pressure with or without proteinuria is a
major cause of maternal morbidity and mortality [8], as
Table 1: Interventions implemented antenatally to prevent or treat maternal infections or conditions reviewed in this paper
Prevention and management of problems during pregnancy
Management of chronic and pregnancy-induced hypertension and prevention of pre-eclampsia
• Calcium supplementation to prevent pregnancy-induced hypertension and pre-eclampsia
• Anti-hypertensives for chronic maternal hypertension
Anti-platelet agents
Heparin and other anti-coagulants
Anti-oxidants
Management of intrahepatic cholestasis
Maternal plasma exchange
Cervical cerclage
Infection control and treatment
Syphilis screening and treatment
Antibiotics and antisepsis in high-risk pregnancies (BV, asymptomatic bacteriuria, and GBS colonisation)
Antibiotics for preterm premature rupture of membranes
Anti-helminthics during pregnancy
Prophylactic anti-malarials
Insecticide-treated nets during pregnancy
Prevention of mother-to-child transmission of HIV
Periodontal careBMC Pregnancy and Childbirth 2009, 9(Suppl 1):S4 http://www.biomedcentral.com/1471-2393/9/S1/S4
Page 3 of 49
(page number not for citation purposes)
well as perinatal morbidity and mortality, worldwide.
Hypertension has been estimated to complicate 5% of all
pregnancies and 11% of first pregnancies, half associated
with pre-eclampsia, and accounting for up to 40,000
maternal deaths annually [9].
Pre-term birth, commonly associated with hypertensive
disorders, is the leading cause of early neonatal death and
infant mortality globally [10]. Inverse relationships
between calcium intake and hypertensive disorders of
pregnancy were observed among the Mayan Indians in
Guatemala [11], whose diet includes corn soaked in lime,
and in Ethiopia, where dietary intake of calcium is also
high [12]; both populations have low incidence of pre-
eclampsia and eclampsia. This evidence, with other epide-
miological and clinical studies [13,14], suggested that
increased calcium intake during pregnancy might reduce
the incidence of hypertensive disorders, including pre-
eclampsia, among women with low calcium intake. As
supplementation is inexpensive and relatively straightfor-
ward, calcium supplementation is attractive as a potential
intervention to reduce the risk of pre-eclampsia. The
mechanisms involved in calcium-mediated effects on
blood pressure reduction are not well understood, but it
has been posited that parathyroid hormone might be
involved in regulating this relationship [15].
Literature-based evidence
Our literature search identified two systematic reviews
and one Cochrane protocol, along with one other RCT
(Table 2). Trumbo et al. [16] evaluated 7 moderate- to
high-quality studies assessing the relationship between
calcium intake and pregnancy-induced hypertension and/
or pre-eclampsia (Additional file 1). The purpose of this
review by the Food and Drug Administration (FDA) was
to make recommendations for the US population and
thus studies carried out in populations with low calcium
intakes and undernutrition were specifically not included.
Four studies showed no reduction in the incidence of
pregnancy-induced hypertension as a result of calcium
supplementation and three showed a reduction. Five of
these studies also examined pre-eclampsia as an outcome
and three of the five showed no reduction in the incidence
of pre-eclampsia from calcium supplementation while the
remaining two showed a reduction. Based on this review,
the US Food and Drug Administration concluded that the
relationship between calcium and risk of hypertension is
inconsistent and inconclusive, and an impact of calcium
intake on the risk of pregnancy-induced hypertension and
pre-eclampsia is unlikely.
Hofmeyr et al. [17] reviewed 12 studies of good quality,
including 5 of the studies in the Trumbo analysis, to assess
the impact of calcium supplementation for preventing
hypertensive disorders in pregnant women. The review
found that calcium supplementation reduced the risk of
Table 2: Impact of calcium supplementation for prevention of PIH and pre-eclampsia on stillbirth and perinatal mortality
Source Location and Type of Trial Intervention Stillbirths and perinatal 
outcomes
Reviews & meta-analyses
Hofmeyr et al. 2007 [17,188] Argentina, USA, Australia,  Ecuador, 
India, Egypt, Peru, South Africa, 
Vietnam.
Meta-analysis (Cochrane) 10 RCTs 
included, N = 15,103 women.
To assess the effects of calcium 
supplementation during pregnancy vs. 
placebo on hypertensive disorders of 
pregnancy and related maternal and 
child outcomes.
SB or death before discharge from 
hospital: RR = 0.89 (95% CI: 0.73–
1.09) [NS]
Trumbo et al. 2007 [16] Argentina, USA, Guatemala, 
Austrália.
Review (FDA). 7 RCTs included, N 
= 6542 women.
To assess the effects of calcium 
supplementation during pregnancy vs. 
placebo on hypertensive disorders of 
pregnancy.
PIH: 3 of 7 RCTs showed reduction 
in PIH with 2 g/day dose, 4 RCTs 
showed no impact.
Pre-eclampsia: 2 of 5 RCTs showed 
reduction in pre-eclampsia with 1.8 
or 2 g/day dose, 3 RCTs showed no 
impact.
Intervention studies
Kumar et al. 2009 [19] India (New Delhi). Lok Nayak 
Hospital.
RCT. N = 524 healthy primigravidas 
with a blood pressure of less than 
140/90 mm Hg between the 12th 
and 25th weeks of gestation.
Compared the impact of 2 g of 
elemental calcium (intervention) vs. 
placebo (controls) from the time of 
enrollment to delivery.
SBR: 5/251 (2.0%) vs. 6/273 (2.2%) 
in intervention and control groups, 
respectively; P = 0.62.BMC Pregnancy and Childbirth 2009, 9(Suppl 1):S4 http://www.biomedcentral.com/1471-2393/9/S1/S4
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high blood pressure (11 trials, N = 14,946 women: RR =
0.70, 95% CI: 0.57–0.86) and pre-eclampsia (12 trials, N
= 15,206 women: RR = 0.48, 95% CI: 0.33–0.69) com-
pared to placebo. Effect on pre-eclampsia was greatest for
high-risk women (5 trials, N = 587 women: RR = 0.22,
95% CI: 0.12–0.42), and those with low baseline calcium
intake (7 trials, N = 10,154 women: RR = 0.36, 95% CI:
0.18–0.70) (Additional file 2). Calcium supplementation
also reduced the composite outcome "maternal death or
serious morbidity" (4 trials, N = 9732 women; RR = 0.80,
95% CI: 0.65–0.97). However, there was no overall effect
on the relative risk of a stillbirth or the baby dying before
discharge from hospital (10 trials, N = 15,141 women: RR
= 0.89, 95% CI: 0.73–1.09) [LOE: 1+]. Another Cochrane
review on calcium supplementation other than for pre-
venting or treating hypertension on pregnancy and infant
outcomes is currently in progress [18].
In India, an RCT by Kumar et al. [19] found no significant
difference in the percentage of stillbirths in healthy prim-
igravidas supplemented with calcium compared to pla-
cebo (2.0% vs. 2.2%, respectively).
Conclusion
The evidence from a range of reasonable studies and a
Cochrane review (Grade B evidence) indicated that cal-
cium supplementation reduced the risk of pre-eclampsia
by 31–67% and gestational hypertension by 30% in cal-
cium-deficient individuals, and also had a concomitant
benefit to maternal health. There was no significant effect
of calcium supplementation in pregnant women on the
risk of stillbirth or the baby dying before discharge from
hospital, regardless of the mother's risk of hypertensive
disorders of pregnancy. The evaluation of the evidence by
Trumbo et al. [16] reflects a more guarded view on the role
of calcium in prevention of hypertension in low-risk
women. Both the Trumbo and the Cochrane review
included a large NIH study (N = 4590) [20] in a well-
nourished US population that found no evidence of ben-
efit in preventing pre-eclampsia. However, the NIH partic-
ipants made up a much larger proportion of the sample
assessed in the Trumbo review than the Cochrane review,
heavily influencing its findings. Reduction in pre-term
birth due to calcium supplementation remains plausible,
particularly given the reduction in the risk of pre-term
birth observed among women at high risk of pre-eclamp-
sia, but this impact remains unproven. The evidence for
an impact of calcium supplementation varies based on
the nutritional status of the population under study. It is
plausible that calcium supplementation is effective in pre-
venting pregnancy-induced hypertension and/or pre-
eclampsia only in calcium-deficient individuals; the
Cochrane review [17] included a number of studies
among undernourished populations and found that the
risk of pre-eclampsia was reduced by half. There are cur-
rently insufficient trials of calcium supplementation in
calcium-deficient populations to assess impact on still-
births conclusively. Future studies must evaluate the
impact of calcium supplementation on a range of perina-
tal outcomes including stillbirths, focused wherever pos-
sible on calcium-deficient populations.
Anti-hypertensives for chronic maternal hypertension
Background
Alone, high blood pressure has little impact on pregnancy
outcomes–nearly 10% of normotensive women experi-
ence abnormally elevated blood pressure at some point
during pregnancy–but sustained elevated blood pressure
may be associated with other complications [21,22].
Between 10 and 15% of maternal deaths in low-/middle-
income countries are associated with hypertensive disor-
ders of pregnancy [23-25], and these conditions also
increase the risk of perinatal mortality as a consequence of
prematurity, poor fetal growth, and other unknown
mechanisms [26-28]. There are several major categories of
hypertensive disorders, including gestational hyperten-
sion or pregnancy-induced hypertension (hypertension
without proteinuria); pre-eclampsia (hypertension with
proteinuria); chronic or essential hypertension (pre-exist-
ing hypertension); and chronic hypertension with super-
imposed pre-eclampsia [29]. Hypertension, hypothesised
to cause fetal distress due to vasoconstriction that reduces
the blood supply across the placenta, or placental abrup-
tion, may result in poor growth or premature delivery,
even when it is mild to moderate. Of all hypertensive dis-
orders of pregnancy, pre-eclampsia/eclampsia has the
highest impact on morbidity and mortality, including
renal or liver failure, clotting disorders, stroke, pre-term
delivery, stillbirth or neonatal death [30].
The pathophysiology of adverse pregnancy outcomes
associated with hypertensive disorders is poorly under-
stood. In pre-eclampsia, the prevailing theory is that poor
placentation results in an ischemic placenta, which
restricts blood and nutrient flow to the fetus. The dysfunc-
tional placenta also releases factors into the mother's
bloodstream that damage maternal organs and vascula-
ture, and cause proteinuria [31,32]. There are no reliable
ways of predicting which women will develop pre-
eclampsia, or which cases of pre-eclampsia will become
eclamptic [33]. However, women with severe hyperten-
sion prior to pregnancy, women who are hypertensive
during the first trimester despite use of antihypertensives,
and women who have had a prior adverse pregnancy out-
come are known to be at high risk of super-imposed pre-
eclampsia (50%–75%), fetal growth restriction (25%–
40%), and placental abruption (10%–20%) [34].
The care of women with hypertensive disorders is com-
plex [21]. The rationale for administering anti-hyperten-BMC Pregnancy and Childbirth 2009, 9(Suppl 1):S4 http://www.biomedcentral.com/1471-2393/9/S1/S4
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sive drugs to pregnant women with high blood pressure is
that these drugs could prevent progression of high blood
pressure to pre-eclampsia, and pre-eclampsia to eclampsia
(seizures), thus reducing the risk of pre-term delivery and
placental abruption and improve fetal growth [33]. The
optimal treatment of chronic hypertension in pregnancy,
including the effectiveness and safety of other anti-hyper-
tensive drugs, such as calcium channel blockers and alpha
agonists, which act primarily by causing vasodilatation,
remains unclear [29].
Literature-based evidence
Our literature search identified 6 Cochrane reviews and 2
other intervention/observational studies (Table 3). Aba-
los et al. [29] undertook a Cochrane review of all RCTs
evaluating any anti-hypertensive drug treatment for mild
to moderate hypertension during pregnancy defined
using objective criteria. Comparisons were of one or more
anti-hypertensive drug(s) with placebo, with no anti-
hypertensive drug, or with another anti-hypertensive
drug, where treatment was planned to continue for at least
7 days (Additional file 3). Forty-six trials (N = 4282
women) were included. Twenty-eight trials compared an
anti-hypertensive drug with placebo/no anti-hypertensive
drug (N = 3200 women), and found a 50% reduction in
risk of low-/middle-income severe hypertension (19 tri-
als, N = 2409 women; RR = 0.50; 95% CI: 0.41–0.61; risk
difference (RD) -0.10 (-0.12 to -0.07); number needed to
treat (NNT) to prevent a case of severe hypertension was
10 (range: 8–13) but no evidence was found for a differ-
ence in the risk of pre-eclampsia (22 trials, N = 2702
women; RR = 0.97, 95% CI: 0.83–1.13). No significant
impact on stillbirths was found (RR = 1.14, 95% CI: 0.60–
2.17) [LOE: 1++]. Another Cochrane review by Magee et
al. [35] compared the effect on perinatal mortality of beta-
blocker vs. placebo/no beta-blocker. Based on 13 trials (N
= 1429 women), there was no effect of beta-blocker usage
on PMR (RR = 1.01, 95% CI: 0.46–2.22) [LOE: 1++]
(Additional file 4). Similarly, Duley et al. [21] reported a
non-significant effect of labetalol vs. hydralazine (RR =
0.50, 95% CI: 0.05–4.94) or similar calcium channel
blockers vs. hydralazine (RR = 1.36, 95% CI: 0.42–4.41)
on risk of fetal or neonatal deaths in pregnant women
[LOE: 1++] (Additional file 5).
In another Cochrane review comparing the impact of cal-
cium channel blockers to any other tocolytic agent in
inhibiting pre-term labour, King et al. 2003 [36] found no
statistically significant difference in PMR (10 trials; N =
810 pregnant women, RR = 1.65, 95% CI: 0.74–3.64)
[LOE: 1+] (Additional file 6). Similarly, Say et al. 1996
[37] compared flunarizine vs. no treatment in pregnant
women either at high risk or with suspected impaired fetal
growth and found a large but non-significant reduction in
PMR (OR = 0.14, 95% CI: 0.00–6.82) [LOE: 1+] (Addi-
tional file 7). Other Cochrane reviews of the effect of
hypertensive treatments on pregnancy outcome are in
progress [38,39].
Among other studies, an RCT in an Australian tertiary
referral maternity hospital by Hennessy et al [40] com-
pared different anti-hypertensive drugs in hypertensive
women (N = 124) and reported three perinatal deaths in
the group given IV hydralazine (5 mg doses) compared to
one perinatal death in the group given mini-bolus diazox-
ide (15 mg doses), but the study was too small for the
results to reach statistical significance [LOE: 1+]. Another
meta-analysis by Meher et al. [41] assessed the impact of
nitric oxide in preventing pre-eclampsia (N=4 RCTs) and
computed a non-significant decrease in risk of perinatal
and neonatal mortality combined compared to untreated
controls (RR = 0.25, 95% CI: 0.03–2.34 [NS]) [LOE: 1+]
(Additional file 8).
Conclusion
While optimal pharmacological therapy of chronic mater-
nal hypertension is highly desirable to improve maternal
outcomes, uncertainty remains about the most optimal
agent and duration of therapy. Among women with mild
to moderate hypertension, anti-hypertensives are effective
in reducing the risk of severe hypertensive episodes in
pregnant women and the evidence from available studies
is of reasonable quality (Grade B evidence). However, if
reductions in severe hypertension were clinically impor-
tant, a downstream impact of reduced perinatal mortality,
pre-term births and caesarean section could be antici-
pated, yet there is no evidence of such an effect [29]. One
possible explanation for this lack of impact is the possibil-
ity of over-treatment with anti-hypertensives. The degree
to which placental blood flow is autoregulated is still
unknown, and some anti-hypertensives are known to
increase the risk of fetal distress arising from reduced uter-
oplacental, umbilical or fetal blood flow [42,43]. Because
of these side effects, particularly when treating severe
hypertension, it is possible that modest reductions in
blood pressure could be of greater benefit to the fetus than
achievement of normal maternal blood pressure using
anti-hypertensives.
Women allocated to an anti-hypertensive, especially beta-
blockers, were less likely to need another agent but more
likely to experience side effects than those allocated pla-
cebo or no anti-hypertensive treatment. Between 8 and 13
women need to be treated with an anti-hypertensive drug
to prevent an episode of severe hypertension. Whether
anti-hypertensive treatment is worthwhile depends on
whether there are associated reductions in the conse-
quences of severe hypertension, such as pre-eclampsia,
eclampsia, maternal stroke, and pre-term birth or associ-
ated outcomes, but the limited data suggest a lack ofBMC Pregnancy and Childbirth 2009, 9(Suppl 1):S4 http://www.biomedcentral.com/1471-2393/9/S1/S4
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impact on stillbirths and perinatal mortality, and preclude
any firm conclusions about intermediate outcomes such
as pre-eclampsia and eclampsia.
The impact of various pharmacological agents on perina-
tal outcomes and stillbirths is unclear and further studies
are needed to define optimal approaches to prevention
Table 3: Impact of anti-hypertensive drugs to treat chronic maternal hypertension on stillbirth and perinatal mortality
Source Location and Type of Study Intervention Stillbirths/Perinatal Outcomes
Reviews and meta-analyses
Abalos et al. 2007 [29] Brazil, Caribbean Islands, Ireland, 
Israel, Italy, South Africa, Sweden, 
UK, USA, Sudan, Argentina, 
Australia, France, India, Venezuela.
Meta-analysis (Cochrane). 43 RCTs 
included.
To assess the effects of anti-hypertensive 
drug treatments for women with mild to 
moderate hypertension during pregnancy 
on pregnancy outcomes.
SBR: RR = 1.14 (95% CI: 0.60, 2.17) 
[NS]
PMR: RR = 0.96 (95% CI: 0.60–
1.54) [NS]
Duley et al. 2006 [21] UK (Northern Ireland, England), 
South Africa, USA, Brazil, The 
Netherlands, Germany, Australia.
Meta-analysis (Cochrane). 13 RCTs 
included.
To compare the impact of different anti-
hypertensive drugs for very high blood 
pressure during pregnancy on pregnancy 
outcomes.
PMR: RR = 0.50 (95% CI: 0.05–
4.94) [NS] in labetalol vs. 
hydralazine groups, respectively.
PMR: RR = 1.36 (95% CI: 0.42–
4.41) [NS] in calcium channel 
blockers vs. hydralazine groups, 
respectively.
King et al. 2003 [36] USA, Spain, France, Israel, The 
Netherlands, Thailand.
Meta-analysis. 10 RCTs RCTs 
included (N = 810 participants).
To assess the effects on maternal, fetal 
and neonatal outcomes of calcium channel 
blockers, administered as a tocolytic 
agent, to women in pre-term labour.
PMR: RR = 1.65 (95% CI: 0.74–
3.64).
Magee et al. 2003 [35] England, Caribbean Islands, Israel, 
France, Scotland, Sweden, USA, 
Argentina, Australia, India, 
Venezuela.
Meta-analysis (Cochrane). 27 RCTs 
included.
To assess whether oral beta-blockers are 
better than placebo, or no beta-blocker, 
and have advantages over other anti-
hypertensives, for women with mild to 
moderate pregnancy hypertension.
PMR: RR = 1.01 (95% CI: 0.46–
2.22) [NS] in beta-blocker vs. 
placebo/no beta-blocker groups, 
respectively.
Meher et al. 2007 [41] Italy.
Meta-analysis. 4 RCTs included.
Compared the impact of nitric oxide vs. 
placebo/no intervention in treatment of 
hypertension in pregnancy.
PMR + NMR: RR = 0.25 (95% CI: 
0.03–2.34) [NS]
[0/65 vs. 2/49 in the nitric oxide 
group vs. the placebo group, 
respectively.]
Say et al. 1996 [37] The Netherlands.
1 RCT included (N = 100 
participants).
Assessed the effects of calcium channel 
blockers on fetal growth and neonatal 
morbidity and mortality in pregnancies 
where impaired fetal growth was 
suspected.
PMR: OR = 0.14 (95% CI: 0.00–
6.82).
Intervention studies
Hennessy et al. 2007 [40] Australia, Sydney, tertiary referral 
maternity hospital.
RCT. N = 124 hypertensive women.
Compared the impact of IV hydralazine (5 
mg doses) to mini-bolus diazoxide (15 mg 
doses) on pregnancy outcomes.
PMR: 3 vs. 1 perinatal deaths in 
hydralazine vs. diazoxide groups, 
respectively. No statistical 
significance data given.
Observational studies
Kanner et al. 1980 [189] Israel, Tel Aviv University Medical 
School.
Prospective cohort study. N = 13 
patients with longstanding 
hypertension during 15 pregnancies.
Measured pregnancy outcomes after 
administering a combination of 
propranolol and hydralazine to subjects 
with essential hypertension in pregnancy.
SB: 1/15 in subjects given 
propranolol+hydralazine. No 
controls.BMC Pregnancy and Childbirth 2009, 9(Suppl 1):S4 http://www.biomedcentral.com/1471-2393/9/S1/S4
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and treatment of hypertension in pregnant women in
appropriate community settings. Despite the wealth of
studies and information available on the impact of anti-
hypertensive therapy on maternal outcomes, there is no
evidence that these drugs reduce the risk of stillbirth.
Anti-platelet agents
Background
Pre-eclampsia is a common and serious complication of
pregnancy that can lead to maternal renal or liver failure,
placental abruption, maternal seizures, and fetal compli-
cations from placental dysfunction and hypoxia including
LBW, SGA, stillbirth, and pre-term delivery [44]. Theo-
rised to arise from a poorly implanted or otherwise abnor-
mal placenta that becomes hypoxic, the factors released
by the damaged placenta into the maternal circulation are
thought to activate platelets and the maternal clotting sys-
tem [45-47]. This platelet activity may occur before symp-
toms of pre-eclampsia develop. Pre-eclampsia has also
been characterised by insufficient levels of the vasodilator
prostacyclin, and excessive production of thromboxane, a
platelet-derived vasoconstrictor which stimulates platelet
aggregation [47]. The role of platelets in pre-eclampsia
suggests that anti-platelet agents, including aspirin, could
prevent or slow development of pre-eclampsia and its
associated adverse pregnancy outcomes.
Biochemically, the anti-thrombotic effect of aspirin res-
luts from its suppression of cyclo-oxygenase. This disrup-
tion interferes with the production of thromboxane A2
(TXA2) and inhibits TXA2-dependent platelet aggregation
[48]. The reduced thromboxane production is thought to
protect against vasoconstriction that can cause ischaemia,
fetal growth restriction, and pathologic placental blood
clots. Aspirin also carries risks: it crosses the placenta, it
inhibits platelet function (thus increasing the risk of
maternal and fetal bleeding), and has been linked with an
increased risk of vascular disruptions including gastro-
schisis and possible premature closure of the ductus arte-
riosus [48]. Given safety concerns, as well as clinical
evidence that a daily dose as small as 30 to 50 mg of aspi-
rin results in virtually complete suppression of platelet
TXA2 synthesis after 7 to 10 days in normal subjects, low
doses of aspirin have been considered sufficient to achieve
anti-platelet activity with minimal risk [49]. Indeed, large
trials have consistently found low-dose aspirin in preg-
nancy to be relatively safe. There is no standard definition
for "low-dose" aspirin, named in reference to standard
aspirin (300 mg), but low-dose regimens typically range
from 50–120 mg/day in pregnant patients.
Literature-based evidence
Our literature search identified one Cochrane, two other
systematic reviews and five other observational/interven-
tion studies on the use of anti-platelet agents to improve
pregnancy outcomes (Table 4). Duley et al. [44] reviewed
59 RCTs (N = 37,560 women) comparing the use of any
anti-platelet agent (e.g., low-dose aspirin or dipyrida-
mole) with either placebo or no anti-platelet agent in
pregnant women at risk of pre-eclampsia (Additional file
9). Anti-platelet agents were associated with a statistically
significant 17% reduction in the risk of pre-eclampsia (46
trials, N = 32,891 women, RR = 0.83, 95% CI: 0.77–0.89),
with statistically significantly greater risk reduction for
high-risk compared to moderate-risk women [risk differ-
ence (RD) 5.2% (-7.5 to -2.9%) vs. RD -0.84% (-1.37 to -
0.3%), respectively]. Higher doses of anti-platelet agents
appeared more effective in preventing pre-eclampsia, as
75 mg/day or less of aspirin (21 trials, N = 26,984
women) reduced risk of pre-eclampsia by 12% (RR = 0.88,
95% CI: 0.81–0.95), compared to reductions of 36% (RR
= 0.64, 95% CI: 0.51–0.80) and 70% (RR = 0.30, 95% CI:
0.15–0.60) for trials evaluating more than 75 mg/day of
aspirin, and trials combining high doses of aspirin with
dipyridamole, respectively. Anti-platelet agents statisti-
cally significantly reduced the RR of pre-term birth (8%
reduction), PMR (14% reduction), and SGA (10% reduc-
tion). However, rates of fetal loss were not statistically dif-
ferent between the two groups (RR = 0.96, 95% CI: 0.78–
1.18) [LOE: 1++].
Askie et al. [50] in a recent meta-analysis evaluated indi-
vidual patient data (N = 32,217 women, N = 32,819 off-
spring) involved in 31 RCTs of pre-eclampsia primary
prevention (Additional file 10). Comparing women
receiving anti-platelet agents to controls, they confirmed a
significant reduction in risk of pre-eclampsia (RR = 0.90,
95% CI: 0.84–0.97), very pre-term delivery (< 34 weeks)
(RR = 0.90, 95% CI: 0.83–0.98), and pregnancy with a
serious adverse outcome (RR = 0.90, 95% CI: 0.85–0.96).
Anti-platelet agents had no significant impact on PMR
(RR = 0.91, 95% CI: 0.81–1.03) [NS]), though a slight
trend toward reduced risk was observed [LOE: 1++].
Conclusion
The overall evidence of anti-platelet agents for pre-
eclampsia is Grade B. Among high-risk women, there is
some evidence from the Cochrane meta-analysis by Duley
et al. [44] that use of low-dose aspirin reduces risk of PIH,
but more research is needed to determine those women
for whom aspirin therapy would be effective. There is
strong evidence that anti-platelet treatment for high-risk
women reduces the risk of pre-eclampsia, though the
number needed to treat is high. The optimal choice and
dosage of anti-platelet agent is unclear, but dosages of
low-dose aspirin appear to be important, and higher
doses in the low-dose range may be more efficacious. In
the Cochrane meta-analysis, dosages of low-dose aspirin
of 75 mg/day or more were associated with greater reduc-
tions in risk of pre-eclampsia, pre-term birth, and small-BMC Pregnancy and Childbirth 2009, 9(Suppl 1):S4 http://www.biomedcentral.com/1471-2393/9/S1/S4
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Table 4: Impact of anti-platelet agents on stillbirth and perinatal mortality
Source Location and Type of Study Intervention Stillbirths/Perinatal 
Outcomes
Reviews and meta-analyses
Askie et al. 2007 [50] USA, Zimbabwe, Italy, Brazil, 
Australia, Jamaica, Spain, UK, 
South Africa, China, Barbados, 
Israel, Japan, France, Belgium, 
Finland.
Meta-analysis (Lancet). 31 RCTs 
(N = 30 563 women) were 
included.
To assess the effectiveness and 
safety of anti-platelet drugs for 
prevention of pre-eclampsia and its 
consequences vs. placebo.
SBR+neonatal death before 
discharge (23 trials): RR = 0.91 
(95% CI: 0.81–1.03) [NS]
[484/15412 vs. 524/15260 in 
intervention vs. control groups, 
respectively.]
Duley et al. 2007 [44], Duley et al. 
2001 [190]
Australia, Austria, Barbados, Brazil, 
Finland, France, Israel, Italy, 
Netherlands, Russia, South Africa, 
UK, USA, Jamaica, Zimbabwe, 
China, Spain, India, Belgium.
Meta-analysis (Cochrane). 42 
RCTs (N = 37,560 women) 
included.
To assess the effectiveness and 
safety of anti-platelet agents 
(intervention group) vs. placebo 
(controls) for women at risk of 
developing pre-eclampsia.
Fetal loss (miscarriage+SB): RR = 
0.96 (95% CI: 0.78–1.18) [NS]
[169/9109 vs. 172/8960 in 
intervention vs. control groups, 
respectively.]
PMR: RR = 0.89 (95% CI: 0.74–
1.08) [NS] [190/8294 vs. 212/
8256 in intervention vs. control 
groups, respectively.]
2001 findings (30 RCTs): Fetal 
loss (miscarriage+SB): RR = 0.86 
(95% CI: 0.75–0.98).
Intervention studies
Beaufils et al. 1991 [191] France.
RCT. N = 323 women at 15–18 
wks amenorrhea at 25 centres 
with prior history of FGR or 
placental abruption.
Compared impact of aspirin vs. 
placebo on birth weight, FGR, 
placental abruption, and stillbirth.
SBR: 1% vs. 5% in intervention vs. 
control groups, respectively.
Mean birth weight difference: 225 
g (95% CI: 129–321 g, P = 0.029)
[mean birth weight 2751 (SD = 
670) vs. 2526 (SD = 848) g in 
intervention vs. control groups, 
respectively.]
FGR: 13% (N = 20) vs. 26% (N = 
19); P < 0.02).
Placental abruption: 5% vs. 8% in 
intervention vs. control groups, 
respectively.
Tempfer et al. 2006 [192] Austria.
Prospective case-control study. N 
= 102 women, N = 50 intervention 
group, N = 52 controls, all with a 
history of idiopathic recurrent 
miscarriage, defined as ≥ 3 
consecutive miscarriages < 20 wks 
gestation without associated 
anatomic, cytogenetic, hormonal, 
and infectious pathologies or anti-
phospholipid syndrome.
To compare a combination 
treatment of prednisone (20 mg/d) 
and progesterone (20 mg/d) for 
the first 12 weeks of gestation, 
aspirin (100 mg/d) for 38 weeks of 
gestation, and folate (5 mg every 
second day) throughout their 
pregnancies (intervention group) 
with no treatment (controls).
Live birth rate: 77% (40/52) vs. 
35% (18/52) in intervention vs. 
control groups, respectively (P = 
0.04).
Observational studies
Backos et al. 1999 [193] UK, tertiary referral clinic.
Prospective observational study. N 
= 150 women with history of 
recurrent miscarriage associated 
with persistently positive tests for 
anti-phospholipid antibodies.
Assessed impact of administration 
of low dose aspirin and low dose 
heparin.
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for-gestational age babies than preparations with 75 mg/
day or less. The safety of dosages of aspirin exceeding this
low-dose range remains unproven and requires further
research.
The impact of anti-platelet agents on risk of stillbirths is
less convincing, although the analysis shows a slight trend
in the direction of benefit. Combination treatment with
aspirin and heparin leads to a higher live birth rate among
women with recurrent miscarriage and anti-phospholipid
antibodies, but the results are statistically non-significant.
Given the many small studies with poor allocation con-
cealment and inadequate blinding, there is a need for
more well-designed RCTs in varied settings and popula-
tions to assess the true effectiveness of aspirin in prevent-
ing fetal loss.
Heparin and other anti-coagulants in high-risk 
pregnancies
Background
Pregnancy and the puerperium are associated with an
increased risk of venous thromboembolism, which may
be treated or prevented using anti-coagulants including
unfractionated or low molecular weight heparin (LMWH)
administered intravenously or subcutaneously. Anti-coag-
ulants may also be used prophylactically for women with
a history of deep venous thrombosis, clotting disorders,
pulmonary embolism, anti-phospholipid antibodies, or
systemic lupus erythematosis, or to preserve pregnancy in
women with a history of unexplained spontaneous preg-
nancy losses. Thrombosis of placental vessels associated
with many of these conditions can cause placental insuffi-
ciency and consequent fetal death [51].
A chief concern regarding anti-coagulant therapy in preg-
nancy is that warfarin, the anti-coagulant of choice for
many chronic conditions, is known to be teratogenic. His-
torically, many pregnant women receiving heparin treat-
ment have also had underlying conditions associated with
stillbirth and adverse fetal outcomes, making clear data
scarce on the impact of heparin (whether unfractionated
or LMWH) in pregnancy, as well as the efficacy of heparin
and other anti-coagulants in preventing pregnancy loss in
women with coagulation disorders or a history of preg-
nancy loss.
Literature-based evidence
Our literature search identified three Cochrane reviews,
one Cochrane protocol, and 19 other intervention/obser-
vational studies (Tables 5, 6). Most studies tested the effi-
cacy of any form of heparin to other anti-coagulants for
indications including anti-phospholipid antibodies with
prior loss, thrombophilias, unexplained repeated preg-
nancy loss, and cardiac indications.
Anti-phospholipid antibodies (including lupus coagulant, anti-
cardiolipids, etc.)
A Cochrane review by Empson et al. [51] evaluated trials
of heparin (N = 13) in pregnant women (N = 849) with a
history of pregnancy loss and anti-phospholipid antibod-
ies or lupus coagulant (Additional file 11). Intravenous
immunoglobulin in conjunction with heparin (3 trials; N
= 58) was associated with higher rates of stillbirth and pre-
maturity compared to unfractionated heparin or LMWH
alone (RR = 2.51, 95% CI: 1.27–4.95), similar to pred-
nisone or aspirin (1 trial; N = 82) [LOE: 1+]. For reducing
pregnancy loss, unfractionated heparin appeared superior
to LMWH when combined with aspirin compared to aspi-
rin alone (RR = 0.46, 95% CI: 0.29–0.71 for unfraction-
ated heparin vs. RR = 0.78, 95% CI: 0.39–1.57 for
LMWH). Varying the dosage of heparin had no impact on
pregnancy loss (1 trial; N = 50). In India, a more recent
RCT [52] also documented higher live birth rates and
birth weights with heparin in combination with aspirin
versus aspirin alone in a study population with poor
obstetric history and elevated anti-cardiolipin antibodies.
However, when comparing the relative impact on preg-
nancy loss (miscarriages + stillbirths) of LMWH versus
unfractionated heparin by Stephenson et al. (1 RCT, N =
26 women) [53] in women with anti-phospholipid anti-
Deligiannidis et al. 2007 [66] Greece.
Prospective study (N = 52 women, 
N = 29 intervention, N = 23 
controls who declined 
intervention).
Anti-thrombotic therapy (low-
dose aspirin and low molecular 
weight heparin) vs. controls.
Fetal death rate (miscarriage+SB): 
OR = 0.10 (95% CI: 0.002–0.98, 
Fisher exact test, 0.04)
[1/29 vs. 17/23 in intervention vs. 
control groups, respectively].
Leduc et al. 2007 [194] Canada (hospital records).
Retrospective cohort study. N = 
110 pregnancies (N = 50 
intervention, N = 60 controls) 
among women (N = 43) with ≥ 1 
pregnancy complicated by severe 
early-onset
pre-eclampsia, placental abruption, 
fetal growth restriction (FGR),
or fetal death.
Anti-coagulant prophylaxis was 
administered using dalteparin in 13 
pregnancies, ASA with dalteparin 
in 26, and ASA alone in 11.
SB: No deaths occurred.
Table 4: Impact of anti-platelet agents on stillbirth and perinatal mortality (Continued)BMC Pregnancy and Childbirth 2009, 9(Suppl 1):S4 http://www.biomedcentral.com/1471-2393/9/S1/S4
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Table 5: Systematic reviews/meta-analyses and intervention studies of the impact of heparin and other anti-coagulants in pregnancy 
on stillbirth and perinatal mortality




Empson et al. 2005 [51] UK, USA, Italy, New Zealand, 
Finland.
Meta-analysis (Cochrane).
Aspirin: 13 RCTs (N = 849 
women) included.
Heparin: 8 RCTs included 
(Women with prior miscarriage 
and anti-phospholipid antibody-
positive). N = 98 in trial of LMWH; 
N = 140 in trial of unfractionated 
heparin.
To assess the impact on pregnancy 
loss of:
1. LMWH plus aspirin 
(intervention) vs. aspirin alone 
(controls).
2. Unfractionated heparin plus 
aspirin (intervention) vs. aspirin 
(controls).
3. Aspirin (intervention) vs. 
placebo or standard care (control)
1. Pregnancy loss: RR = 0.78 (95% 
CI: 0.39–1.57) [NS]
[11/51 vs. 13/47 in intervention vs. 
control groups, respectively].
2. Pregnancy loss: RR = 0.46 (95% 
CI: 0.29–0.71).
[18/70 vs. 40/70 in intervention vs. 
control groups, respectively].
3. Fetal loss (miscarriage+SB): RR 
= 1.05 (95% CI: 0.66–1.68) [NS] 
in intervention vs. control groups, 
respectively.
Thrombophilias
Di Nisio et al. 2005 [60] Finland, France.
Meta-analysis (Cochrane). 1 quasi-
RCT included (N = 20 women). 2 
RCTs and quasi-RCTs (N = 74 
women) included.
To evaluate the efficacy and safety 
of anti-coagulant agents, such as 
aspirin compared to placebo and 
enoxaparin vs. aspirin, in women 
with a history of ≥ 2 spontaneous 
miscarriages or one later 
intrauterine fetal death without 
apparent causes other than 
inherited thrombophilias.
1. Assessed the impact of aspirin 
vs. no treatment on live birth rate.
2. Assessed the effects on live 
birth rate of subcutaneous 
enoxaparin (40 mg/daily) vs. aspirin 
(100 mg/daily) from the 8th week 
of amenorrhoea after positive 
pregnancy test.
1. Live-birth rate: RR = 1.00 (95% 
CI: 0.78–1.29)  [NS] in 
intervention (aspirin) vs. control 
groups (placebo), respectively.
2. Live-birth rate: RR = 10.00 (95% 
CI: 1.56–64.20).
[10/10 vs. 1/10 in enoxaparin vs. 
aspirin groups, respectively].
Gates et al. 2002 [62] UK, Finland.
Meta-analysis (Cochrane). 3 RCTs 
included (N = 40 women).
To assess the effects of 
unfractionated heparin 
(intervention) vs. no treatment 
(controls) on the incidence of 
venous thromboembolic disease.
Fetal death (miscarriage + SB): RR 
= 1.00 (95% CI: 0.07–14.90) [NS] 
[1/20 vs. 1/20 in both groups].
Intervention studies
Anti-phospholipid antibodies
Bar et al. 2000 [54] Israel. High Risk Pregnancy Clinic, 
tertiary hospital.
Case series. Pregnant women (N = 
46) with a history of recurrent 
abortions, intrauterine fetal death 
or IUGR and severe early-onset 
pre-eclampsia.
Compared the impact of LMWH 
(enoxaparin sodium, 40 mg daily) 
in combination with low-dose 
aspirin (100 mg daily) in the first 
trimester (intervention group 1, n 
= 14) vs. the second trimester 
(intervention group 2, n = 17) vs. 
low-dose aspirin alone (controls).
Abortions: 14% vs. 0% vs. 0% in 
intervention group 1, intervention 
group 2, and controls, respectively 
[NS] BMC Pregnancy and Childbirth 2009, 9(Suppl 1):S4 http://www.biomedcentral.com/1471-2393/9/S1/S4
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Glasnovic et al. 2007 [55] Croatia.
Case series with non-pregnant 
controls. Pregnant women (N = 
62) with suspected anti-
phospholipid syndrome (N = 36) 
vs. non-pregnant women (N = 26) 
with secondary anti-phospholipid 
syndrome and previous bad 
reproductive anamnesis.
Studied the impact of treatment 
with LMWH plus low-dose aspirin 
during pregnancy.
Fetal deaths: 0 in all groups.
Goel et al. 2006 [52] India (New Delhi).
RCT. Pregnant women (N = 550) 
with poor obstetric history and 
raised anti-cardiolipin antibodies 
IgG.
Compared the impact of a 
combination of low-dose aspirin 
(80 mg/day) and 5000 IU of 
unfractionated heparin 
subcutaneously every 12 hrs under 
hospital surveillance (intervention) 
vs. low-dose aspirin (80 mg/day; 
controls) on pregnancy outcomes.
Live birth rate: 28/33 (84.8%) vs. 
24/39 (61.5%) in intervention vs. 
control groups, respectively (P < 
0.05).
Malinowski et al. 2003 [56] Poland (Lodz).
RCT. Pregnant women (N = 148) 
suffering from recurrent abortion 
with presence of lupus anti-
coagulant antibodies and/or high 
moderate concentration of anti-
cardiolipin antibodies.
Compared the impact of low-dose 
aspirin + LMWH simultaneously 
(Group 1) vs. LMWH 20 g daily 
(Group 2) vs. low-dose aspirin 75 
mg daily (Group 3).
Live birth (%): 92.5% vs. 81.1% vs. 
89.3% in Groups 1, 2 and 3, 
respectively.
Noble et al. 2005 [57] USA. Academically based 
reproductive health centers.
Prospective, controlled pilot study. 
Pregnant women (N = 50) with ≥ 
3 pregnancy losses and positive 
anti-phospholipid antibody.
Compared the impact of LMWH 
plus low-dose aspirin (Group 1) vs. 
unfractionated heparin plus low-
dose aspirin (Group 2).
Miscarriage: 4/25 (16%) vs. 5/25 
(20%) in Group 1 and Group 2, 
respectively. P = 1.00) [NS] 
Live births: 21/25 (84%) vs. 20/25 
(80%) in Group 1 and Group 2, 
respectively. (P = 1.00) [NS] 
Stephenson et al. 2004 [53] Vancouver. Tertiary referral 
centre.
RCT. Pregnant women (N = 28) 
with anti-phospholipid syndrome.
Compared the impact of LMWH 
(dalteparin; intervention) vs. 
unfractionated heparin (control) 
preconceptionally or early in 
pregnancy on live birth rate.
All women also received low-dose 
aspirin, initiated preconceptionally.
Live birth rate: 9/13 (69%) vs. 4/13 
(31%) in intervention vs. control 
groups, respectively.
Thrombophilias
Brenner, LIVE-ENOX Investigators 
2005. [195]
Israel. Multicentre. 
RCT. Pregnant women (N = 180) 
with thrombophilia and a history 
of recurrent pregnancy loss.
Compared the impact of 
enoxaparin 80 mg/day (40 mg 2× 
daily; intervention) vs. enoxaparin 
40 mg/day (40 mg 1× daily; 
controls).
Live birth rate: 65/83 (78.3%) vs. 
70/83 (84.3%) vs. in the 
intervention vs. comparison 
groups, respectively.
Dendrinos et al. 2007 [65] Greece (Athens).
RCT. Women (N = 62) with a 
history of recurrent pregnancy 
loss and at least one factor of 
thrombophilic disorder.
Compared the impact of 50 IU/kg 
of tinzaparin sodium daily 
(intervention) vs. 100 mg of aspirin 
daily (controls).
New abortions: 6/31 vs. 11/31 in 
intervention vs. control groups, 
respectively; (P = 0.04).
Sarig et al. 2005 [196] Israel.
Non-matched case-control study. 
Pregnant women (N = 87; N = 47 
intervention, N = 40 controls with 
normal pregnancies) with 
thrombophilia and recurrent 
pregnancy loss.
Compared the impact of LMWH 
(enoxaparin) 40 mg daily 
(intervention group 1) vs. 40 mg 
2× daily (intervention group 2) vs. 
no treatment (controls).
Live birth: 38/48 (79%) vs. 32/39 
(82%) in groups 1 and 2, 
respectively [NS] 
Table 5: Systematic reviews/meta-analyses and intervention studies of the impact of heparin and other anti-coagulants in pregnancy 
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Unexplained prior losses
Dolitzky et al. 2006 [70] Israel. University hospitals, general 
hospital, and community health 
clinic.
Multi-centre randomised 
comparative cohort. Pregnant 
women (N = 107) with ≥ 3 
consecutive 1st trimester 
miscarriages or ≥ 2 consecutive 
2nd trimester miscarriages
Compared the impact of LMWH 
enoxaparin (intervention) vs. 
aspirin (controls) on the live birth 
rate.
Live birth rate: RR = 0.92 (95% CI: 
0.58–1.46) [NS] 
[44/54 (81.5%) vs. 42/50 (84%) in 
intervention vs. control groups, 
respectively].
Live birth rate in primary aborters: 
[17/18 (94%) vs. 18/22 (81%) in 
intervention vs. control groups, 
respectively].
Cardiac indications
Lee et al. 2007 [68] Korea (Daegu).
Retrospective study. Pregnant 
women (N = 25) with mechanical 
heart valve replacement between 
1997 and 2005.
Compared the impact of LMWH 
nadroparin (7,500 U 2× daily) 6–12 
wks of gestation and close-to-term 
only, and coumarin derivatives 
were used with aspirin at other 
times (exposed) vs. coumarin 
derivatives throughout pregnancy 
(unexposed).
Fetal death (miscarriage + SB): 2/
23 (8.7%) vs. 4/8 (50%) in the 
exposed and unexposed groups, 
respectively (P = 0.011).
Table 5: Systematic reviews/meta-analyses and intervention studies of the impact of heparin and other anti-coagulants in pregnancy 
on stillbirth and perinatal mortality (Continued)
bodies or lupus anti-coagulant, while a trend towards
reduced pregnancy loss using LMWH was observed (RR =
0.44, 95% CI: 0.18–1.08 [NS]), the results did not reach
statistical significance. Several other small studies com-
paring heparin plus low-dose aspirin to aspirin alone
reported no difference in live birth rates or fetal loss
between groups [54-57].
Several studies compared heparin treatment to no treat-
ment for anti-phospholipid antibodies. A cohort study in
Israel of enoxaparin versus no treatment [58] showed a
three-fold higher odds of having a live birth among
women given enoxaparin compared to controls (OR =
3.03; 95% CI: 1.12–8.36). Among primary aborters, the
odds of live birth were improved even more dramatically
with enoxaparin compared to controls. Ruffatti et al [59]
assessed the efficacy and safety of calcium heparin versus
no treatment to prevent fetal loss in women with a history
of pregnancy loss and anti-phospholipid antibodies (N =
53), and reported a 100% live birth rate in patients receiv-
ing heparin versus 24.52% live birth rate in patients
receiving no treatment (P < 0.001) [LOE: 3].
Two reviews included analyses of the impact of aspirin
versus placebo or no treatment in patients with anti-phos-
pholipid antibodies. Di Nisio et al. [60] reviewed RCTs
and quasi-RCTs that assessed the effect of anti-coagulant
treatment (either aspirin, unfractionated heparin and low
molecular weight heparin compared to placebo or other
treatment) on the live-birth rate in women with a history
of at least two spontaneous miscarriages or one later intra-
uterine fetal death without apparent causes other than
inherited thrombophilias (Additional file 12). Extracting
relevant data from two eligible trials (N = 242), the study
found no impact of aspirin vs. placebo on live birth rate
(RR = 1.00, 95% CI: 0.78–1.29) [LOE: 1+]. Empson et al.
[51] examined outcomes of aspirin given to maintain
pregnancy in women with prior miscarriage and anti-
phospholipid syndrome (APL) (N = 11 RCTs), and found
no statistical difference in impact compared with placebo
or usual care (RR = 1.05, 95% CI: 0.66–1.68) [LOE: 1+].
Thrombophilias
A Cochrane protocol by Dodd et al. [61] indicates that a
review evaluating anti-thrombotic therapy for improving
maternal or infant health outcomes in women at risk of
placental dysfunction is in progress, and another
Cochrane review by Gates et al. [62] of heparin as proph-
ylaxis for thromboembolic disease did not identify
enough deaths to conduct statistical analysis (Additional
file 13). We also reviewed an observational study of anti-
thrombotic therapy [63] including antithrombin, protein
C or protein S deficient women (N = 37), which compared
thromboprophylaxis with either LMWH or unfraction-
ated heparin before 16 weeks and after 36 weeks' gesta-
tion plus a Vitamin K antagonist from 16 to 36 weeks until
after delivery. The study documented no fetal losses
among antithrombin, protein C or protein S deficient
women who received treatment, 7% losses among non-
deficient women who received treatment, and 45% in
untreated antithrombin-deficient women (adj. RR = 0.07,
95% CI: 0.001–0.7, P = 0.02 in women who received
treatment vs. women who did not, respectively).
Di Nisio et al. [60] conducted a Cochrane review of RCTs
and quasi-RCTs of anti-coagulant treatments in womenBMC Pregnancy and Childbirth 2009, 9(Suppl 1):S4 http://www.biomedcentral.com/1471-2393/9/S1/S4
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Table 6: Observational studies on the impact of heparin and other anti-coagulants in pregnancy on stillbirth and perinatal mortality




Carp et al. 2003 [58] Israel.
Cohort study. Pregnant women (N 
= 85) with ≥ 3 consecutive 
pregnancy losses and a hereditary 
thrombophilia who conceived (N = 
85 delivered; N = 38 miscarried).
Compared the impact of enoxaparin 
40 mg (intervention) vs. no treatment 
(controls) on pregnancy outcomes.
Live births: OR = 3.03 (95% CI: 
1.12–8.36); P < 0.02.
[26/37 (70.2%) vs. 21/48 (43.8%) in 
intervention vs. control groups, 
respectively].
(Among primary aborters) Live 
birth rate: OR = 9.75 (95% CI: 
1.59–52.48; P < 0.008).
(Among primary aborters ≥ 5 
miscarriages) Live birth rate: 
61.6% vs. 18.2% in intervention vs. 
control groups, respectively [NS].
Franklin and Kutteh 2002 [197] USA. 2 centres.
Prospective cohort study. Pregnant 
women (N = 79) with ≥ 2 
consecutive pregnancy losses and 
anti-phospholipid antibodies (2 
intervention groups: group 1 had 
recurrent pregnancy loss + anti-
phospolipid antibodies; group 2 had 
other positive anti-phospholipid 
antibodies).
Compared the impact of heparin and 
aspirin (intervention) vs. aspirin alone 
(group 3; controls). Intervention 
group 1 was treated with heparin and 
aspirin; intervention group 2 was 
treated with heparin or aspirin; group 
3 received aspirin alone.
Viable infants: 19/25 (76%) vs. 18/
28 (64%) vs. 12/26 (46%) in groups 
1, 2 and 3, respectively (P = 0.03 
for group 1 vs. group 3).
Ruffatti et al. 1997 [59] Italy (Padova).
Prospective cohort study. Pregnant 
women (N = 53) with ≥ 2 
consecutive miscarriages during 
first trimester and/or 1 fetal death 
during last two trimesters.
Compared the pregnancy success 
rate with calcium heparin alone, self-
administered subcutaneously 3× daily 
at dosages 15,000–37,500 IU vs. rate 
prior to therapy.
Live birth: 100% vs. 24.52% in the 
calcium heparin vs. prior to 
therapy (P < 0.0001).
Malformations: 0/53
30/37 examined placentas 
(81.08%) showed signs of 
thrombotic events.
Thrombophilias
Deligiannidis et al. 2007 [66] Greece.
Cohort study. Pregnant women (N 
= 52) with thrombophilia.
Compared the impact of LMWH plus 
low-dose aspirin (intervention) vs. no 
treatment (controls).
Fetal death (miscarriage+SB): OR 
= 0.10 (95% CI: 0.002–0.98).
[1/29 vs. 17/23 in intervention vs. 
control groups, respectively].
Folkeringa et al. 2007 [63] Netherlands.
Prospective, family cohort study. 
Pregnant women (N = 376) with (N 
= 37) and without (N = 18) 
hereditary deficiencies of 
antithrombin protein C or protein 
S.
Compared the impact of 
thromboprophylaxis with 
unfractionated or LMWH < 16 wks 
and > 36 wks of gestation, and a 
vitamin K antagonist from 16–36 wks 
and after delivery (intervention #1) 
vs. no treatment (controls). 
Additionally compared same 
treatment in women deficient for 
antithrombin protein C or protein S 
(intervention #2) vs. no treatment in 
non-deficient women (controls).
Fetal death (miscarriage + SB): adj. 
RR = 0.07 (95% CI: 0.001–0.7, P = 
0.02) in intervention #1 group vs. 
controls, respectively.
Fetal death (miscarriage+SB): 0% 
in deficient women with 
thromboprophylaxis versus 45% in 
deficient women without (P = 
0.001) and 7% in non-deficient 
women without 
thromboprophylaxis (P = 0.37).BMC Pregnancy and Childbirth 2009, 9(Suppl 1):S4 http://www.biomedcentral.com/1471-2393/9/S1/S4
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Cardiac indications
Kawamata et al. 2007 [69] Japan.
Retrospective study. Women (N = 
12; N = 16 pregnancies) with 
mechanical heart valve 
replacement.
Assessed the impact of changing 
warfarin treatment to heparin at 6–13 
wks of gestational age; administration 
continuously adjusted according to 
the activated partial thromboplastin 
time level up to the time of delivery.
Fetal death (miscarriage + SB): 1/
16 (at 30 wks).
Kim et al. 2007 [67] South Korea (Seoul).
Retrospective study. Women (N = 
27; N = 41 pregnancies) with a 
mechanical valve replacement.
Compared the impact among three 
groups: group 1 (N = 5) took 
warfarin throughout the pregnancy, 
group 2 (N = 18) took heparin 
throughout the pregnancy, and group 
3 (N = 18) took heparin in the 1st 
trimester and warfarin from 12–20 
wks gestation.
SBR: 2/5 (40%) vs. 1/18 (5.6%) vs. 
8/18 (44.4%) in groups 1, 2, and 3, 
respectively.
Safety
Sorensen et al. 2000 [71] Denmark. Population-based.
Retrospective cohort study using 
national databases. Pregnant 
women receiving LMWH (N = 66) 
or no drugs (N = 17,259) between 
1991–98.
Compared the impact of LMWH 
(exposed) vs. no prescriptive drugs 
(unexposed).
SBR: 0/66 (0%) vs. 204/17,259 
(1.2%) in the exposed vs. 
unexposed groups, respectively.
Pre-term: OR = 2.11 (95% CI: 
0.96–4.65) [NS]
LBW and malformations: no 
increased risk.
Table 6: Observational studies on the impact of heparin and other anti-coagulants in pregnancy on stillbirth and perinatal mortality
 (Continued)
with a history of fetal loss without apparent causes other
than inherited thrombophilias (2 trials; N = 242 women
with inherited thrombophilias and prior loss). The review
included a study in France by Gris et al. [64] that deter-
mined that enoxaparin was superior to low-dose aspirin
in preventing stillbirth, as the live birth rate among
women with prior pregnancy losses was 10 times higher
in the enoxaparin group compared to controls given low-
dose aspirin (RR = 10.00, 95% CI: 1.56–64.20) [LOE: 1-
]. Another RCT [65] testing tinzaparin sodium (an
LMWH) versus aspirin showed a lower rate of miscarriage
in the LMWH group (N = 31) compared to the aspirin
group (N = 31), though statistically insignificant (RR =
0.55, 95% CI: 0.23–1.29) [LOE: 2+]. When compared to
no treatment, LMWH was associated with dramatically
lower risk of fetal death. Significantly lower risk of fetal
death was reported by a small study (N = 52) comparing
LMWH plus aspirin to no treatment (OR = 0.10, 95% CI:
0.002–0.98) [66][LOE:2-]. In a cohort study in the Neth-
erlands [63], thromboprophylaxis with heparin or LMWH
reduced the fetal death rate to 0% in antithrombin-pro-
tein-C- or protein-S-deficient women, compared with
45% in deficient women given no treatment (P = 0.01)
[LOE:2-].
Cardiac indications
Other observational studies have evaluated fetal out-
comes after anti-coagulant therapy for cardiac problems
or following cardiac surgery. Several studies explored
pregnancies in women after cardiac valve replacement,
including a Korean study [67] which compared the impact
on birth outcomes of warfarin (N = 5), heparin (N = 18)
and heparin for the first trimester followed by warfarin
until 20 weeks gestation (N = 18). The lowest SBR
occurred in the heparin-only group (5.6% in the heparin
versus 40.0% and 44.4% in the warfarin and heparin-war-
farin groups, respectively) [LOE:2-]. In a safety study of
nadroparin among women with replaced heart valves, Lee
et al. [68] reported a significantly lower fetal death rate
(8.7% vs 50%, P = 0.01) among women treated with
nadroparin (N = 23) compared with coumarin plus aspi-
rin (N = 8) [LOE: 3]. Kawamata et al. [69] reported that
among women with heart valve replacements (N = 12; N
= 16 pregnancies) switched from warfarin to heparin
treatment from 6–13 weeks of gestation until delivery,
only one fetal death occurred [LOE: 3].
Repeated unexplained prior loss(es)
Only one study was identified that tested low molecular
weight heparin in women with repeated unexplained
losses excluding women with thrombophilias or anti-
phospholipid antibodies. This RCT by Dolitzky et al. in
Israel among women with at least 3 prior first-trimester or
at least 2 prior second-trimester losses [70] (N = 107)
found no difference in live birth rates between enoxaparin
and aspirin.BMC Pregnancy and Childbirth 2009, 9(Suppl 1):S4 http://www.biomedcentral.com/1471-2393/9/S1/S4
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Safety
Heparin appears to be safe throughout pregnancy. In Den-
mark, Sorensen et al. [71] used national prescription,
birth registry, and hospital discharge data to analyze the
safety of LMWH use in pregnancy, finding no increased
risk of stillbirth, malformations, or LBW among pregnant
women treated with LMWH compared with women who
received no prescription drugs in pregnancy [LOE: 2+].
New meta-analyses
We conducted independent meta-analyses on available
RCTs (N = 2) comparing the efficacy of LMWH enoxa-
parin (N = 64) to aspirin (N = 60) on live birth rate in
women with recurrent pregnancy loss; finding no
improvement of LMWH over aspirin in live birth rates (RR
[fixed] = 1.17, 95% CI: 0.96–1.42) (RR [random] = 2.37,
95% CI: 0.22–24.93) (Figures 1, 2).
Meta-analysis (Forest plot) of impact of LMWH versus aspirin on live birth rate in women with recurrent pregnancy loss (Ran- dom model) Figure 2
Meta-analysis (Forest plot) of impact of LMWH versus aspirin on live birth rate in women with recurrent preg-
nancy loss (Random model).
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Meta-analysis (Forest plot) of impact of LMWH versus aspirin on live birth rate in women with recurrent pregnancy loss (Fixed  model) Figure 1
Meta-analysis (Forest plot) of impact of LMWH versus aspirin on live birth rate in women with recurrent preg-
nancy loss (Fixed model).
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We also compared the impact on pregnancy loss of
unfractionated heparin plus aspirin versus aspirin alone
(3 RCTs; N = 212 women) in women with antiphosphol-
ipid antibody or lupus anticoagulant. The combination
treatment with unfractionated heparin was associated
with a 56% reduction in pregnancy loss (RR [Fixed] =
0.44, 95% CI: 0.29–0.65)(RR [Random] = 0.44, 95% CI:
0.30–0.66) (Figures 3 and 4).
Conclusion
The use of thromboprophylaxis in women with a history
of at least two miscarriages or one later intrauterine fetal
death without apparent causes other than inherited
Meta-analysis (Forest plot) of impact of unfractionated heparin and aspirin versus aspirin alone on pregnancy loss (miscarriages  plus stillbirths) in women with antiphospholipid antibody or lupus anticoagulant (Random model) Figure 4
Meta-analysis (Forest plot) of impact of unfractionated heparin and aspirin versus aspirin alone on pregnancy 
loss (miscarriages plus stillbirths) in women with antiphospholipid antibody or lupus anticoagulant (Random 
model).
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Meta-analysis (Forest plot) of impact of unfractionated heparin and aspirin versus aspirin alone on pregnancy 
loss (miscarriages plus stillbirths) in women with antiphospholipid antibody or lupus anticoagulant (Fixed 
model).
Study or Subgroup






Heterogeneity: Chi² = 0.52, df = 2 (P = 0.77); I² = 0%
Test for overall effect: Z = 4.05 (P < 0.0001)
Total (95% CI)
Total events
Heterogeneity: Chi² = 0.52, df = 2 (P = 0.77); I² = 0%
Test for overall effect: Z = 4.05 (P < 0.0001)





































UH and aspirin Aspirin Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours experimental Favours controlBMC Pregnancy and Childbirth 2009, 9(Suppl 1):S4 http://www.biomedcentral.com/1471-2393/9/S1/S4
Page 17 of 49
(page number not for citation purposes)
thrombophilia remains a matter of debate (overall evi-
dence Grade C). While some clinicians prescribe anti-
thrombotic agents as the last therapeutic resort in these
women, this approach is largely based on data from non-
randomised trials and on indirect evidence of an anti-
coagulation benefit in women with anti-phospholipid
antibody syndrome and recurrent pregnancy loss. Accord-
ing to a recent review [60], insufficient evidence exists
(only 2 poorly controlled RCTs with questionable exter-
nal validity, within which only a small subgroup of
women met the inclusion criteria) to recommend the use
of anti-thrombotic agents in women with unexplained
recurrent pregnancy losses without anti-phospholipid
antibodies. While aspirin appears not to improve gesta-
tional outcomes in these women [72,73], LMWH
appeared to increase the live birth rate relative to aspirin
[64].
Despite the small size of the study groups, our results sup-
port the assertion that heparin, whether unfractionated or
LMWH, is not teratogenic and can be safely used through-
out pregnancy where indicated for maternal conditions
including thrombophilias. For women with anti-phos-
pholipid antibodies, unfractionated heparin plus aspirin
is superior to aspirin alone [51]. In women without anti-
phospholipid syndrome, LMWH alone was more effective
than aspirin [60]. Used appropriately as anti-coagulant
therapy for clotting disorders and anti-phospholipid syn-
drome, heparin shows strong evidence of benefit in reduc-
ing stillbirths and perinatal mortality.
Anti-oxidant treatment to prevent or treat pre-eclampsia
Background
Anti-oxidants, including free radical scavengers and
enzymes that inhibit peroxidase reactions which produce
free radicals [74], protect proteins and enzymes from oxi-
dation and destruction by free radicals, and help to main-
tain cellular membrane integrity. Examples include
vitamin C (ascorbate), vitamin E (tocopherols), caroten-
oids, glutathione, glutathione peroxidase, catalase, and
superoxide dismutase. Women with pre-eclampsia have
been documented to have lower plasma and placental
concentrations of anti-oxidants [75,76], hypothesised to
be due to placental underperfusion. Theoretically, anti-
oxidants could increase women's resistance to oxidative
stress, which depletes maternal stores of anti-oxidants. In
cases where placental ischaemia causes subsequent oxida-
tive stress, such supplements might limit systemic and
uteroplacental endothelial damage to maternal vascula-
ture and organs, thus slowing or preventing the progres-
sion of pre-eclampsia.
Literature-based evidence
Our literature search identified three related Cochrane
reviews, all conducted by the same researcher, and one
RCT (Table 7). Rumbold et al. [77] (10 RCTs, 5 high-qual-
ity, N = 6533 women) identified trials of anti-oxidants
and found that most tested combined vitamin C and E
therapy (Additional file 14). There was no significant dif-
ference between anti-oxidant and control groups in risk of
pre-eclampsia (RR = 0.73, 95% CI: 0.51–1.06; 9 RCTs, N
= 5446 women) or any other primary outcome, including
severe pre-eclampsia (RR = 1.25, 95% CI: 0.89–1.76; 2
RCTs, N = 2495 women), pre-term birth (< 37 weeks) (RR
= 1.10, 95% CI: 0.99–1.22; 5 RCTs, N = 5198 women),
SGA infants (RR = 0.83, 95% CI: 0.62–1.11; 5 RCTs, N =
5271 babies) or pregnancy loss (RR 1.32, 95% CI 0.92 to
1.90; four trials, 5144 babies). Women allocated to anti-
oxidants were more likely to self-report abdominal pain
late in pregnancy (RR = 1.61, 95% CI: 1.11–2.34; 1 RCT,
N = 1745 women), require anti-hypertensive therapy (RR
= 1.77, 95% CI: 1.22–2.57; 2 RCTs, N = 4272 women) and
require an antenatal hospital admission for hypertension
(RR = 1.54, 95% CI: 1.00–2.39 [NS]; 1 RCT, N = 1877
women). However, for the latter two outcomes, this was
not clearly reflected in an increase in any other hyperten-
sive complications. An earlier Cochrane review by Rum-
bold and Crowther [78] (Additional file 15) assessed the
impact of Vitamin C supplementation alone during preg-
nancy (5 RCTs, N = 766 women). No difference was seen
between women supplemented with vitamin C alone or
in combination with other supplements compared with
placebo for the risk of stillbirth (RR = 0.87, 95% CI: 0.41–
1.87, 3 RCTs, N = 539 women), PMR (RR = 1.16, 95% CI:
0.61–2.18, 2 RCTs, N = 238 women), birth weight
(weighted mean difference (WMD) -139.00 g, 95% CI: -
517.68 to 239.68, 1 RCT, N = 100 women) or IUGR (RR
= 0.72, 95% CI: 0.49–1.04, 2 RCTs, N = 383 women).
Women supplemented with vitamin C compared with
placebo were at increased risk of pre-term birth (RR =
1.38, 95% CI: 1.04–1.82, 3 RCTs, N = 583 women). Rum-
bold and Crowther [79] (Additional file 15) also exam-
ined the impact of Vitamin E supplementation (4 RCTs, N
= 566 women at risk of, or with, pre-eclampsia). All trials
assessed vitamin E in combination with other supple-
ments and two trials were published as abstracts only.
Meta-analysis showed no impact of Vitamin E on risk of
stillbirth (RR = 0.77, 95% CI: 0.35–1.71, 2 RCTs, N = 339
women), neonatal death (RR = 5.00, 95% CI: 0.64–39.06,
1 RCT, N = 40 women), PMR (RR = 1.29, 95% CI: 0.67–
2.48, 1 RCT, N = 56 women), pre-term birth (RR = 1.29,
95% CI: 0.78–2.15, 2 RCTs, N = 383 women), IUGR (RR
= 0.72, 95% CI: 0.49–1.04, 2 RCTs, N = 383 women) or
birth weight (weighted mean difference -139.00 g, 95%
CI: (-)517.68-239.68 g, 1 RCT, N = 100 women), using
fixed-effect models.
Roberts et al. [80] reported results from a double-blind
RCT of Vitamins C and E versus placebo administered to
low-risk nulliparous women (N = 9969). The study foundBMC Pregnancy and Childbirth 2009, 9(Suppl 1):S4 http://www.biomedcentral.com/1471-2393/9/S1/S4
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no differences in the primary outcome, defined as either
severe hypertension or pregnancy-related hypertension
with at least one of the following: SGA, hepatic or renal
dysfunction, eclampsia, stillbirth, or neonatal death
before discharge (6.1% vs. 5.8% in antioxidant vs. pla-
cebo groups, respectively). Additionally, there was no
impact on the incidence of pre-eclampsia (7.2% vs. 6.7%
in antioxidant vs. placebo groups, respectively).
Conclusion
The overall level of evidence for these studies for impact
on pregnancy outcomes is Grade D. Based on this limited
evidence, with no trials conducted in under-nourished
populations, there appears to be little benefit of anti-oxi-
dants for the prevention of pre-eclampsia and its related
complications, as studies have not reported consistent
impact. There is no evidence suggesting that anti-oxidant
supplements, specifically vitamins C or E or both, avert
stillbirths or other perinatal complications such as SGA or
neonatal death. Given that the studies reviewed here may
not be generalisable to under-nourished populations,
studies are needed that test anti-oxidant supplementation
in such populations to ascertain whether treatment can
impact rates of adverse pregnancy outcomes. Interven-
tions included in this section and paper have aimed to
prevent pre-eclampsia/eclampsia; the management of pre-
eclampsia/eclampsia in pregnancy has been dealt with in
Paper 5 [81].
Management of intrahepatic cholestasis in pregnancy
Background
Maternal intrahepatic chlolestasis is a liver disorder that
causes maternal morbidity during pregnancy, usually
manifest as itching (pruritis) as well as an increased risk of
associated perinatal mortality. Cholestasis is the most
common liver disorder specific to pregnancy and is a prin-
cipal cause of jaundice in the third trimester. Cholestasis
is associated with significantly increased risk of fetal dis-
tress, pre-term delivery and stillbirth; however, the mech-
anisms by which cholestasis causes these complications
are still unclear, and treatment strategies are thus largely
empiric. The risks of adverse pregnancy outcomes associ-
ated with cholestasis increase near term and are unrelated
to the severity of symptoms. Early delivery (at 36 weeks
gestation) is an intervention that may be considered in
cases of severe intrahepatic cholestasis, particularly if
there is suspected fetal distress and lung maturity has been
confirmed. Administering Vitamin K to the baby immedi-
ately after birth may help prevent intracranial bleeding.
There is limited evidence about the effectiveness of other
treatments, including guar gum, activated charcoal, S-ade-
nosyl-L-methionine (SAMe) and ursodeoxycholic acid
(UDCA), in alleviating maternal itching or improving
perinatal outcomes.
Table 7: Impact of anti-oxidant supplementation on stillbirth and perinatal mortality
Source Location and Type of Study Intervention Stillbirths/Perinatal Outcomes
Reviews and meta-analyses
Rumbold et al. 2008 [77] UK, Australia, South Africa.
Meta-analysis (Cochrane). 4 
RCTs included.
Compared impact of 
supplementation with any anti-
oxidants vs. control/placebo.
Fetal death rate (miscarriage+SB): RR = 1.32 
(95% CI: 0.92–1.90) [NS]
[66/2569 vs. 50/2575 in intervention vs. control 
groups, respectively.]
Rumbold et al. 2005 [78] UK, South Africa
Meta-analysis (Cochrane). 3 
RCTs included
Compared impact of 
supplementation with Vitamin C 
vs. control/placebo.
SBR: RR = 0.87 (95% CI: 0.41–1.87) [NS]
[9/268 vs. 11/271 in intervention vs. control 
groups, respectively.]
Rumbold et al. 2005 [79] UK, South Africa
Meta-analysis (Cochrane). 2 
RCTs included.
Compared impact of 
supplementation with Vitamin E vs. 
control/placebo.
SBR: RR = 0.77 (95% CI: 0.35–1.71)
[8/168 vs. 11/171 in intervention vs. control 
groups, respectively.]
Intervention studies
Roberts et al. 2008 [80] USA.
RCT. N = 9969 low-risk 
nulliparous women 9–16 weeks 
gestation at enrolment.
Compared impact of 
supplementation with Vitamin C 
(1000 mg/day) plus Vitamin E (400 
IU/day) vs. placebo.
Severe hypertension or pregnancy-related 
hypertension with at least one of the following: 
SGA, hepatic or renal dysfunction, eclampsia, 
stillbirth, or neonatal death before discharge: 
6.1% vs. 5.8% in antioxidant vs. placebo groups, 
respectively/
Pre-eclampsia (7.2% vs. 6.7% in antioxidant vs. 
placebo groups, respectively).BMC Pregnancy and Childbirth 2009, 9(Suppl 1):S4 http://www.biomedcentral.com/1471-2393/9/S1/S4
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Literature-based evidence
Our literature search identified no Cochrane reviews and
four trials assessing interventions for maternal intrahe-
patic cholestasis in pregnancy (Table 8). Three of these
four were RCTs and compared the impact of different
treatments for intrahepatic cholestasis on stillbirths or
perinatal mortality. Binder et al. [82] compared S-adeno-
syl-L-methionine (SAMe) monotherapy (N = 78), ursode-
oxycholic acid (UDCA) (N = 78) and combined therapy
(N = 78) and documented no perinatal deaths in any
group. Comparing UDCA, dexamethasone, and placebo
in a cohort of women (N = 130), Glantz et al. [83]
recorded only one intrauterine fetal death, which occurred
in the placebo group. In Chile, Palma et al. [84] tested
UDCA versus placebo, reporting only one perinatal death
in the placebo group (0/8 in the UDCA group versus 1/7
in the placebo group).
The fourth trial that we identified [85] prospectively eval-
uated the effect of a management protocol for cholestasis
including surveillance for presence of meconium using
transcervical amnioscopy after 36 weeks, semi-weekly
non-stress testing and amniotic fluid indices, and induc-
tion of labour at 37 weeks. Comparing the study's rate of
fetal death with historical series data using expectancy and
conventional monitoring of fetal well-being in pregnan-
cies complicated by cholestasis, the fetal death rate was
significantly lower in the study group than in the series
data (1/218 vs. 14/888, respectively, P = 0.045), and the
Caesarean section rate was not significantly different
[LOE: 2+].
Conclusion
The intervention trial reviewed above that compared a
management protocol in patients with intrahepatic
obstetric cholestasis to standard monitoring of fetal well-
being suggests that such protocols can reduce the SBR
without increasing the cesarean delivery rate. However,
this evidence is inconclusive (overall Grade D), and more
studies are needed. There remains a need for studies to
identify the mechanisms by which cholestasis causes peri-
natal mortality, as well as safety and efficacy studies for
optimal pharmacological treatment regimens to treat
cholestasis. The impact of different treatments for
cholestasis vis-à-vis stillbirths or perinatal mortality
remains inconclusive, as there are only a few trials on the
subject.
Table 8: Impact of management of intrahepatic cholestasis on stillbirth and perinatal mortality
Source Location and Type of Study Intervention Stillbirths/Perinatal 
Outcomes
Intervention studies
Binder et al. 2006 [82] Czech Republic.
RCT. Singleton pregnancies (N = 
78) < 36 wks with a moderate or 
severe form of cholestasis 
recruited 1999–2004.
Compared the impact among three groups 
[SAMe (S-adenosyl-L-methionine) 
monotherapy (group 1), UDCA 
(ursodeoxycholic acid) (group 2), and 
combined therapy (group 3)] on PMR.
PMR: 0/25 vs. 0/26 vs. 0/27 in 
groups 1, 2 and 3, respectively 
[NS]
Glantz et al. 2005 [83] Sweden.
Double-blind, placebo-controlled 
RCT. Pregnant women (N = 130; 
N = 47 UDCA, N = 36 
dexamethasone, N = 47 placebo) 
with cholestasis.
Compared the impact on perinatal outcomes 
of treatment of cholestasis with UDCA 
(intervention #1), or dexamethasone 
(intervention #2), vs. placebo (controls).
Fetal death (miscarriage + SB): 0/
47 vs. 0/36 vs. 1/47 in 
intervention group #1, 
intervention group #2, and 
controls, respectively.
Palma et al. 1997 [84] Chile. Secondary case-referral 
center.
RCT. Pregnant women (N = 15) 
with early-onset obstetric 
cholestasis.
Compared the impact on perinatal outcomes 
of treatment with UDCA (intervention) vs. 
placebo (controls).
SBR: 0/8 vs. 1/7 in intervention vs. 
control groups, respectively.
Roncaglia et al. 2002 [85] Italy (Milan). University hospital.
Intervention trial using prospective 
cases. Pregnant women (N = 218) 
with obstetric cholestasis and 
historical series data.
Compared the effect of a management 
protocol for cholestasis incorporating 
transcervical amnioscopy, standard 
monitoring of fetal well-being with 2× weekly 
non-stress testing and AFI indices, and 
induction of labour at 37 weeks if high-risk 
(intervention) vs. historical controls on 
obstetric outcome.
SBR: 0/218 vs. 14/888 in 
intervention vs. control groups, 
respectively (P = 0.045).BMC Pregnancy and Childbirth 2009, 9(Suppl 1):S4 http://www.biomedcentral.com/1471-2393/9/S1/S4
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Maternal plasma exchange
Background
Maternal autoimmune or coagulation disorders may trig-
ger the production of embryotoxic antibodies, which
jeopardise pregnancy and lead to intrauterine death.
These conditions include anti-D antibodies produced fol-
lowing maternal Rhesus alloimmunisation, lupus anti-
coagulant and anti-cardiolipin that mark anti-phospholi-
pid syndrome, and anti-Ro/SSA and anti-La/SSB antibod-
ies in systemic lupus erythematosus, among others [86].
Plasma exchange, or plasmapheresis, often in conjunction
with steroid treatment or intravenous administration of
immunoglobulins, is a means to remove or suppress cir-
culating autoimmune or anti-coagulation factors in the
blood and have been employed in a range of situations
[87]. Reducing these embryotoxic factors could prevent
pregnancy loss, and provide an important alternative
when intrauterine transfusion for Rhesus alloimmunisa-
tion, or anti-coagulant therapy (e.g., heparin +/- low dose
aspirin) for anti-phospholipid syndrome fails. In recur-
rent abortion involving the presence of anti-P antibodies
in mothers with the rare P blood group [88], plasmapher-
esis has proven effective in reducing pregnancy loss.
Literature-based evidence
Our review identified two observational studies. No
Cochrane or other systematic review was identified on the
subject. El-Haieg et al. [89] conducted a study which
assessed plasmapheresis plus low dose prednisone on
obstetric and neonatal outcomes among unsuccessfully
treated pregnant women with documented anti-phos-
pholipid syndrome. There were no perinatal deaths [LOE:
3]. According to the study of Angela et al. [90], fourteen
high-risk cases of Rh alloimmunised women were treated
by intensive plasma exchange on the cell separator
throughout their pregnancies. The expected stillbirth rate
in this series as determined by their past obstetric histories
and anti-D levels was 62%. Intrauterine transfusion was
given to only two of the infants and both were later still-
born [LOE: 3].
Conclusion
Only two case series were identified, one on plasma
exchange for severe Rh disease and the other (prednisone
and plasmapheresis) for anti-phospholipid syndrome
(Grade D evidence). Further large-scale studies are needed
to investigate the effect of plasma exchange on stillbirths/
perinatal mortality. Although robust evidence of an
impact on stillbirths and perinatal deaths is lacking,
plasma exchange commenced early in pregnancy may be
an alternative therapy for severe Rh haemolytic disease




Cervical incompetence is estimated to occur in approxi-
mately 1% of the obstetric population, and 8% of women
who experience repeated spontaneous abortions [91];
true rates are difficult to assess given a range of definitions
but are likely higher. Cervical incompetence is increas-
ingly recognised as associated with a continuum of com-
plications including second-trimester miscarriage as well
as pre-term birth. Incompetent cervix may be diagnosed
presumptively following recurrent unexplained second
trimester losses or pre-term births. However, increasingly,
incompetent cervix is assumed when a short cervix is diag-
nosed via transvaginal ultrasound. Cervical cerclage, the
surgical process of stitching the cervix closed to prevent
further shortening and dilatation, can be either planned
(history-indicated), urgent (ultrasound-indicated) or
emergent (exam-indicated, generally in an emergency sit-
uation) [92]. In women with 3 or more pre-term births or
second-trimester losses, history-indicated cerclage is typi-
cally placed between 12–14 weeks of gestation. Evidence
suggests that ultrasound-indicated cerclage, on the other
hand, may be most effective when placed after 14 weeks
but before 24 weeks of gestation [93].
The two most common transvaginal methods for place-
ment of a cervical stitch are modifications of procedures
developed by Shirodkar and McDonald [94,95]. The Shi-
rodkar technique involves an incision in the cervix at the
level of the internal os and requires dissecting the bladder
free; the cervix is then encircled with a purse-string suture
through the broad cervical ligament. The McDonald tech-
nique does not require dissecting the bladder free, using
an encircling suture around the cervix to approximate the
level of the internal os. Ultrasound examination post-cer-
clage has shown that the Shirodkar procedure achieves
longer cervical length than the McDonald procedure [96],
but no differences in rates of pre-term birth have been
observed between the two methods [97]. In women with
short and/or scarred cervixes, or where vaginal cervical
cerclage has not worked, placement of the stitch can be
difficult; in these women, transabdominal cervical cer-
clage can be performed, but patients require caesarean sec-
tion delivery.
Despite being widely practiced, cerclage is controversial
because its benefits in maintaining pregnancy and pre-
venting pre-term birth have been marginal. A number of
meta-analyses and reviews including pooled estimates of
cerclage impact have found conflicting evidence of impact
on pre-term birth rates associated with cerclage [92,98].
However, recent good-quality trials of ultrasound-indi-
cated cerclage for short cervix, including a large, rigorous
RCT, have demonstrated a statistically significant impact
of cervical cerclage in reducing pre-term birth rates [99].BMC Pregnancy and Childbirth 2009, 9(Suppl 1):S4 http://www.biomedcentral.com/1471-2393/9/S1/S4
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Cerclage has been studied primarily for its impact on pre-
term birth. The procedure may also reduce stillbirth,
though this has not been a principal focus of cerclage
studies to date.
Literature-based evidence
For this review, we identified two systematic reviews and
5 other intervention and observational studies of cervical
cerclage that reported impact on stillbirths and/or perina-
tal mortality (Table 9). One Cochrane review by Drakeley
et al. [92] compiled all adequately randomised RCTs (6
trials, N = 2175 women) comparing cervical cerclage with
expectant management or no cerclage during pregnancy,
as well as trials comparing different cerclage techniques,
alone or with other interventions (Additional file 16). In
the 4 included trials of prophylactic cerclage versus no cer-
clage, pooled results revealed no overall reduction in peri-
natal death (RR = 0.80, 95% CI: 0.48–1.36), pregnancy
loss, or pre-term delivery rates before 28 and before 34
weeks. Cervical cerclage was associated with mild pyrexia,
increased tocolytic use, and increased hospital admis-
sions, but had no associated serious morbidities [LOE:
1++]. Another meta-analysis of RCTs of cerclage [100] (N
= 7 trials, N = 2091 women) found no significant impact
of cerclage on pregnancy loss or death before discharge
from hospital in singleton pregnancies (OR = 0.81; 95%
CI: 0.60–1.10 [NS]), though the small sample size indi-
cated a need for additional large trials (Additional file 17).
However, in the logistic regression analysis, an adverse
association of cerclage with perinatal deaths was observed
for multiple pregnancies (OR 5.88; 95% CI 1.14–30.19),
suggesting cerclage should be avoided in multiple preg-
nancies. Neither indication for cerclage nor obstetric his-
tory was found to have a statistically significant impact on
the effect of cerclage [LOE: 1++]. The only other RCT com-
pared the impact of outpatient versus inpatient cerclage
[101]; live birth rate was slightly higher among the inpa-
tient group but the difference was not statistically signifi-
cant.
A retrospective study of prophylactic cerclage in multiple
gestation by Strauss et al. reported no impact on perinatal
mortality, and a non-statistically significantly elevated
risk of perinatal morbidity in higher-order gestations
(quadruplets and quintuplets) [LOE: 2-].
Three observational studies highlighted the effectiveness
of transabdominal cerclage as an alternative after unsuc-
cessful transvaginal cerclage. Fick et al. [102] [LOE: 2+],
and Gesson-Paute et al. [103][LOE: 2-] reported live birth
rates after transabdominal cerclage of 96%, and 93%
respectively, compared to 18% [102] and 17% [103]
before the procedure. Debbs et al. [104] conducted a sim-
ilar study and reported a 93% live birth rate after the pro-
cedure [LOE: 3].
Conclusion
The systematic reviews on cervical cerclage are of suffi-
ciently high quality to permit a Grade B assessment, but
are concerned primarily with impact on pre-term birth,
and report statistically non-significant impact on still-
birth. Perinatal mortality outcomes reported by the large
meta-analysis on cerclage [92] showed no conclusive evi-
dence of benefit on stillbirth. The largest reviewed study in
this meta-analysis by the MRC/RCOG [105] reported a
significant reduction in very pre-term deliveries, and more
recent data from a large RCT [99] has demonstrated a pos-
itive impact on pre-term birth in pregnant women with
ultrasound-confirmed short cervix. This definitive trial
indicates that ultrasound-indicated cervical cerclage is of
benefit to reduce risk of preterm birth. Cerclage is not rou-
tinely indicated in multiple pregnancies [100]. It is possi-
ble that cervical cerclage may reduce pregnancy loss in
singleton pregnancies [100], particularly high-risk preg-
nancies, but it is unlikely that another large RCT like the
Owen study [99] will be conducted to evaluate the impact
of cerclage on stillbirth. It should be noted that measure-
ment of the impact of cerclage on pregnancy outcomes is
biased by the frequent exclusion from studies of women
with true cervical incompetence. Cervical cerclage is cur-
rently inconclusive evidence of benefit for preventing still-
birth despite its proven impact on pre-term birth. Future
studies may confirm reductions in perinatal mortality and
help identify the sub-groups of women in whom it is most
effective (e.g., ultrasound-indicated cerclage).
Infection control and treatment
Anti-helminthics during pregnancy in hookworm-endemic 
regions
Background
Two species of hookworm, Ancylostoma duodenale and
Necator Americanus, typically infect humans. Found
throughout the tropics and subtropics, hookworm infes-
tation is significantly associated with anaemia in women
and children in endemic areas. Anaemia during preg-
nancy is associated with premature delivery, LBW, mater-
nal ill health, and maternal death [106]. In areas endemic
for hookworm, routine antenatal anti-helminthic therapy
could reduce the prevalence of anaemia in pregnancy,
hypothetically preventing pregnancy losses associated
with anaemia. In two studies of anti-helminthic treatment
of women in pregnancy, the mean decrease in haemo-
globin concentration from the first to the third trimester
in women receiving a single dose of albendazole was 6.6
g/L less than women receiving placebo (P = 0.003)
[107,108], but another study showed no impact on hae-
moglobin level [109]. Where the prevalence of hookworm
is more than 20% to 30%, the WHO recommends that
pregnant women receive treatment (mebendazole, alben-
dazole, levamisole or pyrantel) after the first trimester. At
present, however, this is not a widely accepted controlBMC Pregnancy and Childbirth 2009, 9(Suppl 1):S4 http://www.biomedcentral.com/1471-2393/9/S1/S4
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strategy in part because of a lack of data on the safety of
anti-helminthics. Potential teratogenicity is the principal
concern surrounding use of anti-helminthics, as side
effects are few [110]. The limited studies on this subject
have found no evidence of fetal malformations attributa-
ble to anti-helminthics used during pregnancy, but some
studies have recommended that anti-helminthics not be
used during the first trimester as a precaution until larger
safety studies in pregnancy are available [111-113].
Table 9: Impact of cervical cerclage on stillbirth and perinatal outcomes
Source Location and Type of Study Intervention Stillbirths/Perinatal 
Outcomes
Reviews and meta-analyses
Drakeley et al. 2003 [92] Netherlands, France, UK, South 
Africa.
Meta-analysis (Cochrane). 6 RCTs 
included (N = 2059 women).
Assessed the effects of cervical 
cerclage (intervention) vs. no cerclage 
(controls).
PMR: RR = 0.80 (95% CI: 0.48–
1.36) [NS]
[24/1035 vs. 31/1024 in 
intervention vs. control groups, 
respectively.
Jorgensen et al. 2007 [100] Netherlands, USA, Nigeria, UK, 
France, Hungary, Norway, Italy, 
Belgium, Zimbabwe, South Africa, 
Iceland, Ireland, Canada, Brazil 
Slovenia, Greece and Chile.
Meta-analysis. 7 RCTs included (N 
= 2091 women).
Assessed the effects of cervical 
cerclage (intervention) vs. no cerclage 
(controls).
(Singleton gestations) Pregnancy 
loss or death before hospital 
discharge: OR = 0.81 (95% CI: 
0.60–1.10) [NS]
(Multiple gestations) Pregnancy 
loss or death before hospital 
discharge: OR = 5.88 (95% CI: 
1.14–30.19).
Intervention studies
Blair et al. 2002 [101] West Indies.
RCT. Pregnant women (N = 50) 
with cervical incompetence.
Compared the impact of cervical 
cerclage between inpatient care for 3 
days post-procedure, spending 3 days 
in hospital post-procedure 
(intervention) vs. outpatient bed rest 
(controls). Both groups given 
salbutamol tablets postoperatively for 
tocolysis.
Live birth rate: 20/23 vs. 18/23 
(86.9% vs. 78.3%) in intervention 
vs. control groups, respectively 
[NS]
Jaswal et al. 2006 [198] India.
Quasi-RCT. Pregnant women (N = 
37) being expectantly managed for 
placenta previa.
Compared the impact of cervical 
cerclage (intervention) versus no 
cerclage (controls).
PMR: 0/18 vs. 8/19 in intervention 
vs. control groups, respectively (P 
< 0.01).
Observational studies
Debbs et al. 2007 [104] USA.
Retrospective case series. Pregnant 
women (N = 75) with negative 
evaluation for recurrent pregnancy 
loss and ≥ 1 previous unsuccessful 
transvaginal cerclage.
Assessed the impact of transabdominal 
cerclage on birth outcomes.
Live birth rate: 96% after 
transabdominal cerclage.
Fick et al. 2007 [102] USA.
A cohort study. Pregnant women 
(N = 88 women; N = 9 
pregnancies) with transabdominal 
cerclage.
Compared the live birth rate before 
and after transabdominal cerclage.
Live birth rate: 93% vs. 18% after 
vs. cerclage, respectively; P < 
0.001).
Gesson-Paute et al. 2007 [103] France.
Retrospective study. 
Transabdominal cerclages (N = 12) 
performed from 1988–2005.
Compared the live birth rate during 
the period where transabdominal 
cerclage was performed vs. the pre-
cerclage period.
Live birth rate: 93% vs. 17% after 
vs. before cerclage, respectively.BMC Pregnancy and Childbirth 2009, 9(Suppl 1):S4 http://www.biomedcentral.com/1471-2393/9/S1/S4
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Literature-based evidence
Several studies of deworming in pregnancy have demon-
strated benefits on maternal nutrition outcomes and
anaemia [109,114,115]. Our literature review identified
two intervention studies and one observational study
(Table 10).
De Silva et al. [116] assessed the effect of mebendazole
therapy during pregnancy on birth outcomes in a cross-
sectional retrospective study in Sri Lanka in 1995. Still-
births and perinatal deaths were significantly less com-
mon in the mebendazole group (19/1000 vs. 33/1000; RR
= 0.55, 95% CI: 0.4–0.77), as was the proportion of LBW
infants (1.1 vs. 2.3%, RR = 0.47, 95% CI: 0.32–0.71). A
slightly higher, but statistically non-significant, rate of
congenital defects was found in women who had taken
the drug in the first trimester [LOE: 2+]. In contrast,
another study by Gyorkos et al. [113] comparing antena-
tal mebendazole (500 mg single dose) given with iron
supplements vs. placebo with iron supplementation did
not show any statistically significant differences between
the mebendazole group (N = 28) and the placebo group
(N = 31) in rates of miscarriages, malformations, still-
births, early neonatal deaths and pre-term births [LOE:
2+]. However, unpublished data from a study of anti-
helminthic treatment, maternal anaemia, and birth
weight in Nepal [117] showed a statistically significant
reduction in neonatal mortality associated with 2 doses of
albendazole during pregnancy compared to controls (OR
= 0.54, 95% CI: 0.37–0.78) [LOE: 2++].
Conclusion
Mebendazole therapy should be avoided during the first
trimester pending further evidence on safety. The overall
quality of evidence from the literature reviewed is Grade
C, however there is some evidence of impact of deworm-
ing on stillbirths and other perinatal outcomes. Maternal
deworming holds promise for improving the health of
pregnant women in low-/middle-income countries where
intestinal helminthiases are endemic. Consonant with the
findings of the studies we reviewed, the Lancet Maternal
and Child Undernutrition Series recommends deworming
during pregnancy in specific, situational contexts (i.e.,
where prevalence of helminthiases and iron-deficiency
Table 10: Impact of anti-helminthics on stillbirth and perinatal mortality
Source Location and Type of Study Intervention Stillbirth/Perinatal mortality 
outcomes
Intervention study
Gyorkos et al. 2006 [113] Peru (Amazon region).
RCT. Data on adverse birth 
outcomes (N = 1042 births).
To compare of the impact of antenatal 
mebendazole (500 mg single dose; 
intervention) plus iron supplement vs. placebo 
plus iron supplement (controls) on the 
occurrence of adverse birth outcomes.
SBR: 8 vs. 4 in intervention vs. 
control groups, respectively. [NS]
ENND: 3 vs. 6 in intervention vs. 
control groups, respectively. [NS]
PMR: 22/1000 vs. 20.2/1000 in 
intervention and control groups, 
respectively (P = 0.840). [NS]
Pre-term: 28 vs. 31 respectively (P 
= 0.664). [NS]
Christian et al. 2004 [117] Nepal (Sarlahi).
RCT.
Compared the impact of two doses of 
albendazole in pregnancy (intervention) vs. no 
treatment (controls) on birth outcomes.
NMR: OR = 0.54 (95% CI: 0.37–
0.78) [unpublished data]
Observational Study
De Silva et al. 1999 [116] Sri Lanka, hospital based.
Cross-sectional survey.
Compared impact on major congenital defects, 
stillbirth, perinatal death, and LBW among 
babies of mothers who had taken mebendazole 
during pregnancy (intervention) with those 
whose mothers had not taken an anti-helmintic 
(controls).
PMR: OR = 0.55 (95% CI: 0.4–
0.77)
[19/1000 vs 33/1000 in 
intervention vs. control groups, 
respectively].
LBW: OR = 0.47 (95% CI: 0.32–
0.71)
[1.1 vs 2.3% in intervention vs. 
control groups, respectively].
Major congenital malformations: 
OR = 1.24 (95% CI: 0.8–1.91, P = 
0.39) [NS]
[97/5275 vs 26/1737 in 
intervention vs. control groups, 
respectively].BMC Pregnancy and Childbirth 2009, 9(Suppl 1):S4 http://www.biomedcentral.com/1471-2393/9/S1/S4
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anaemia are high) [118]. Given the promising but incon-
clusive findings of a recent Cochrane review [110], further
RCTs, especially effectiveness trials, of maternal anti-
helminthic therapy reporting a range of pregnancy and
infant outcomes are needed.
Syphilis screening and treatment
Background
Reported rates of syphilis vary greatly worldwide. Preva-
lence is generally lower in high-income countries than in
low-/middle-income countries. In 1990, the incidence of
primary and secondary syphilis in the United States was
20 per 100,000 population, far less than the disease bur-
den of 360 per 100,000 estimated for parts of Africa
[119,120]. Syphilis remains a major cause of avoidable
perinatal death in many low-/middle-income countries
despite being treatable, and despite the WHO recommen-
dation that all pregnant women be tested as part of rou-
tine ANC. Among pregnant women with untreated early
syphilis, 25% of pregnancies result in stillbirth and 14%
in neonatal death, an overall perinatal mortality of about
40% [121]. In early untreated syphilis, a pregnant woman
has a 70% chance of transmitting the infection to her fetus
[122]. Even after effective screening, many pregnant
women with syphilis remain inadequately treated because
of delays in initiating treatment or patient non-adherence.
Testing for syphilis within antenatal clinics is a strategy
that makes test results available immediately so that early
treatment can be administered, which could improve
treatment of syphilis and reduce perinatal mortality [123].
Literature-based evidence
We identified 1 Cochrane review and 8 interventional,
quasi-experimental, or observational studies (Table 11)
addressing the impact of syphilis screening and treatment
on perinatal outcomes, the effectiveness of recommended
penicillin treatment regimens, and issues associated with
testing and treatment adherence. Unfortunately, the
Cochrane review by Walker [124] assessing the impact of
antibiotic treatment of syphilis in pregnancy did not
report perinatal mortality outcomes, as none of the stud-
ies identified (N = 29) met the review's eligibility criteria
for comparability.
Impact of screening and treatment on perinatal mortality
In a Swaziland hospital, Guinness et al [125] assessed
how testing results and subsequent treatment for mater-
nal prenatal syphilis serostatus impacted outcomes.
Almost one-third of women (87/283; 31%) were possibly
syphilis seropositive (TPHA-positive and RPR-negative); a
smaller proportion (37/283; 13%) showed conclusive
syphilis infection (TPHA-positive and RPR-positive) at
prenatal testing. Perinatal mortality was highest among
women with untreated active syphilis (7/24; PMR = 290/
1000). Among women with possibly active syphilis, PMR
was 50/1000, compared with 30/1000 among seronega-
tive women. Screening and treatment reduced PMR by
34%, but the intervention would have been even more
effective if treatment had reached the 65% of mothers
with active syphilis who were missed, as well as study par-
ticipants' sexual partners [LOE: 3].
In Kenya, Temmerman et al. [126] assessed the impact of
an antenatal syphilis control programme on pregnancy
outcome, confirming the adverse effect of syphilis infec-
tion on stillbirth. Of patients tested for syphilis (N =
12,414), 3% (N = 377) were RPR-positive; 296 of these
were also TPHA-positive. Syphilis seropositive women
had a higher risk of adverse obstetric outcome, defined as
stillbirth or LBW (OR 4.1, 95% CI: 2.4–7.2). Antenatal
treatment of RPR reactive women with single-dose benza-
thine penicillin G (2.4 million units) reduced the risk of
adverse outcome, but women who remained RPR-positive
after treatment had worse outcomes than uninfected
mothers (OR = 2.5, P < 0.05). There was no statistical dif-
ference in pregnancy outcome based on gestational age at
treatment [LOE: 3].
Syphilis treatment strategies
Treatment for maternal syphilis with single-dose IM ben-
zathine penicillin is being implemented in many parts of
sub-Saharan Africa in conformity with the 1993 Centers
for Disease Control and Prevention (CDC) treatment
guideline recommending a single dose of benzathine pen-
icillin G (2.4 million units) for primary, secondary, and
early latent syphilis in pregnancy, and three doses one
week apart for late latent syphilis and latent syphilis of
unknown duration. Watson Jones et al. [127] studied the
effectiveness of this regimen in a Tanzanian cohort (N =
1688 pregnant women), comparing birth outcomes
between high-titer, low-titer, and seronegative women.
When treated, there was no statistically significant
increased risk of adverse pregnancy outcome (stillbirth or
LBW) comparing high-titer (OR = 0.76, 95% CI: 0.4–1.4)
or low-titer women (OR = 0.95, 95% CI: 0.6–1.5) to
seronegative women. [LOE: 2+].
Donders et al. [128] administered 0, 1, 2 or 3 benzathine
penicillin G intramuscular (IM) injections to HIV-nega-
tive black urban women with syphilis (N = 180) in South
Africa. Pregnancy outcomes were significantly better
among women receiving 2 or more doses of penicillin
than women receiving 0 or 1 dose. However, excluding
patients treated with oral penicillin derivatives and adjust-
ing for duration of treponemicidal levels, the study found
an association of treponemicidal coverage of 3 weeks or
less with decreased birth weight (2748 vs. 3130 g, P =
0.004) and higher rates of perinatal mortality (RR = 20.5;
95% CI: 2.3–184) and pre-term birth (RR = 8.5; 95% CI:BMC Pregnancy and Childbirth 2009, 9(Suppl 1):S4 http://www.biomedcentral.com/1471-2393/9/S1/S4
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Table 11: Impact of syphilis testing and treatment on stillbirth and perinatal mortality
Source Location and Type of Study Intervention Stillbirths/Perinatal 
Outcomes
Reviews and meta-analyses
Walker et al. 2001 [124] None.
Meta-analysis (Cochrane). 29 RCTs 
and quasi-RCTs reviewed, 0 studies 
included.
Assessed the impact of antibiotic 
treatment for syphilis during 
pregnancy.
No data, 0 eligible studies.
Intervention studies
Bique et al. 2000 [130] Mozambique, ANC clinics.
Case-control study. 4 suburban 
ANC clinics (2 intervention clinics, 
2 control clinics).
Pregnant women (N = 929; N = 453 
intervention, N = 476 controls) 
with positive RPR.
Compared the impact of an 
intervention offering RPR testing with 
immediate on-site treatment of 
seropositive cases with 2.4 million IU 
benzathine penicillin by specially 
trained nurse-midwives. The study 
offered to treat partners of 
intervention group as well. Controls 
were offered routine syphilis 
screening protocol requiring testing at 
a separate lab, return visits, and 
payment for treatment (< 50% 
compliance), with no partner 
treatment option.
PMR: 13/1000 vs 34/1000 in 
intervention vs. control groups, 
respectively (P = 0.03).
Fetal death (miscarriage+SB): 13/
1000 vs. 26/1000 (P = 0.159) 
[NS]
Donders et al. 1997 [128] South Africa (Pretoria), hospital-
based.
Prospective cohort study. HIV-, 
RPR+ black urban pregnant women 
(N = 212; N = 135 received ≥ 1 
injection)
Assessed dosage impact of 0–3 weekly 
IM injections of benzathine penicillin G 
on perinatal outcomes.
PMR secondary to congenital 
syphilis: RR = 20.5 (95% CI: 2.3–
184, P = 0.0015).
[0 injections: 7/55 (13%)
1 injection: 2/19 (11%)
2 injections: 1/24 (4.2%)
3 injections: 2/82 (2.4%)]
Adjusted when Treponemicidal 
coverage was < 3 wks
Myer et al. 2003 [123] South Africa (Hlabisa district, rural 
KwaZulu Natal), PHC clinics.
Cluster RCT. 7 pairs of clinics. 
Pregnant women (N = 549).
Compared the impact of on-site 
syphilis testing complemented by 
laboratory confirmation vs. laboratory 
testing alone.
PMR: adj. RD: -0.9%; 95% CI: (-) 
4.4-2.7, P = 0.31) [NS]
[33/1000 (18/549) vs. 51/1000 (8/
157) in intervention clinics vs. 
control clinics, respectively.]
Rotchford et al. 2000 [129] South Africa (Hlabisa district, rural 
KwaZulu Natal), ANC clinics.
Cluster RCT. 12 clinics. Pregnant 
women (N = 1783) screened for 
syphilis (N = 158 RPR+; 9% 
prevalence) at first ANC visit 
(mean: 24 wks); RPR+ women 
followed for pregnancy outcome 
(data available for N = 142 (90%); N 
= 30 had no treatment; N = 96 had 
all 3 doses penicillin)
Assessed impact on PMR of 
inadequate maternal syphilis 
treatment in presence of adequate 
screening.
PMR: 15/142
[0 or 1 dose penicillin: 11/43 
(260/1000)
≥ 2 doses penicillin: 4/99 (40/
1000)]
Dose-response relationship 
observed. (P = 0.0001)
PMR risk reduction:
1 dose: 41% reduction
2 doses: 65% reduction
3 doses: 79% reduction
Watson Jones et al. 2002 [127] Tanzania (Mwanza), ANC clinic.
Case-control study. Pregnant 
women (N = 1688; N = 133 high-
titre [RPR titre ≥ 1:8, TPHA/FTA+]; 
N = 249 low-titre [RPR titre < 1:8, 
TPHA/FTA+], N = 950 seronegative 
controls).
To examine the effectiveness of 
treatment for maternal syphilis with 
single-dose IM benzathine penicillin 
(2.4 million units).
Birth outcomes were compared 
SBR: 23/1000 vs. 25/1000 in 
treated high-titer women vs. 
seronegative women.
LBW: 6.3% vs. 9.2% in treated 
high-titer women vs. seronegative 
women.
Adverse pregnancy outcome 
(combined SBR+LBW): OR = 
0.76 (95% CI: 0.4–1.4) [NS].BMC Pregnancy and Childbirth 2009, 9(Suppl 1):S4 http://www.biomedcentral.com/1471-2393/9/S1/S4
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2.5–28) compared with treponemicidal coverage lasting
longer than 3 weeks [LOE: 2-].
Rotchford et al. [129] demonstrated the impact on perina-
tal mortality of inadequate treatment for maternal syphi-
lis despite adequate screening. In a study population with
9% syphilis prevalence, Rotchford used linear and cate-
gorical modeling to confirm a dose response protective
relationship of penicillin on PMR. One dose reduced the
risk by 41%, two doses by 65% and three doses by 79%,
compared with no doses. Among those receiving at least
one dose, mean delay to the first dose was 20 days. Among
those fully treated, mean delay to treatment completion
was 34 days [LOE: 2++].
On-site testing and treatment compliance
On-site syphilis testing in ANC clinics may prove an effec-
tive strategy to circumvent problems initiating and com-
pleting antibiotic treatment. Myer et al. [123] studied the
impact of on-site syphilis testing on treatment delays and
rates as well as perinatal mortality. Among women seek-
ing ANC with available test results (N = 7134), 793
(11.1%) tested positive for syphilis. Women at interven-
tion clinics completed treatment 16 days sooner on aver-
age (95% CI: 11–21 days), though there was no
significant difference in the proportion receiving adequate
treatment at intervention and control clinics (64 vs. 69%,
respectively), or in PMR (3.3% vs 5.1% in intervention vs.
control clinics; adjusted risk difference [RD]: (-)0.9%;
95% CI: (-)4.4-2.7) [LOE: 2++].
Bique et al. [130] assessed treatment initiation and com-
pliance following RPR testing in seropositive pregnant
women (N = 929) attending intervention or control clin-
Observational studies
Delport et al. 1993 [199] South Africa (Pretoria), ANC clinic.
Descriptive study. Kalafong 
Hospital. Pregnant women (N = 
1237) attending ANC.
Assessed the sensitivity, specificity, 
negative and positive predictive values 
of the RPR test at ANC compared 






Negative predictive value: 99.5%
Positive predictive value: 64.7%.
Guinness et al. 1988 [125] Swaziland (Mbabane), Public health 
unit
Prospective cohort study. Pregnant 
women (N = 283) tested at ANC 
enrollment: N = 37 (13.1%) TPHA+ 
and RPR+; N = 87 (30.7%) TPHA+ 
and RPR-.
Assessed the impact of antenatal 
screening on perinatal mortality 
attributable to syphilis. Mothers were 
tested prenatally and again at delivery; 
prenatal test found to have sensitivity 
= 36% and predictive accuracy = 48%.
PMR (untreated active syphilis): 
219/1000 (7/32).
12/172 seronegative women had 
active syphilis (late 
seroconversion or false negative 
prenatal test results): 4/12 
experienced perinatal death.
PMR: 46/1000 (4/87) vs. 28/1000 
(4/415) in TPHA+/RPR- vs. 
syphilis-seronegative women.
Screening reduced expected 
syphilis-attributable PMR from 
3.5% to 2.3% (65% of mothers 
with active syphilis missed 
treatment; sexual partners were 
not treated).
Temmerman et al. 2000 [126] Kenya (Nairobi), maternity hospital.
Prospective case control study. 
Women (N = 12414) delivering at 
Pumwani Hospital were RPR tested 
(3%, N = 377 were RPR-positive). 
TPHA testing confirmed syphilis 
infection (N = 296). Equal numbers 
of seronegative women also 
enrolled; records examined for 
syphilis testing and treatment during 
pregnancy.
Assessed the impact of an antenatal 
syphilis control programme on 
pregnancy outcome.
Adverse obstetric outcome 
(LBW or SB): OR = 4.1 (95% CI: 
2.3–7.5, P < 0.001).
[22.5% vs. 6.6% in untreated 
syphilis-positive vs. uninfected 
mothers, respectively.]
LBW: OR = 4.0 (P < 0.0001) in 
untreated syphilis-seropositive 
mothers vs. uninfected mothers, 
respectively.
SBR: OR = 3.3 (P = 0.028) in 
untreated syphilis-seropositive 
mothers vs. uninfected mothers, 
respectively.
OR = 2.5 in treated syphilis-
seropositive mothers vs. 
uninfected mothers, respectively 
(P < 0.05).
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ics. Women attending intervention clinics were given
health education about syphilis, on-site RPR testing and
post-test counseling from a specially trained nurse-mid-
wife, with encouragement to notify partners to come for
free treatment. Women attending control clinics had
standard RPR testing, entailing a multi-step, multi-pro-
vider process over a longer time period, and had to pay for
their own treatment, resulting in compliance below 50%.
PMR was significantly higher in the control group than in
the intervention group (1.3% vs. 3.4% in intervention vs.
control groups, respectively; P = 0.030) [LOE: 2-].
Conclusion
The nature of studies available for syphilis screening and
treatment do not permit more than a Grade D evidence
rating and it is recognised that classic RCTs are not possi-
ble. However, syphilis during pregnancy is a major cause
of avoidable stillbirth and other adverse birth outcomes
in many low-/middle-income countries, and interven-
tions in terms of screening and treating syphilis are recom-
mended for inclusion in endemic populations, as syphilis
testing and treatment shows some evidence of impact on
stillbirth. When treated with the appropriate dose of intra-
muscular benzathine penicillin, treatment effectively
reduces perinatal mortality [129,128] without risk of drug
resistance. However, operational issues associated with
treatment complicate the formulation of screening and
treatment recommendations. Allergy to penicillin may
pose problems for acceptability of treatment, but can be
addressed with desensitisation therapy. There are a few
studies on antibiotics other than penicillin for treatment
of maternal syphilis; other drugs may offer alternative
treatment options. In terms of service delivery, the studies
reported did not support using on-site syphilis testing in
addition to laboratory-based testing, although on-site
testing may be the only feasible way to offer syphilis inter-
ventions in settings where laboratory facilities are lacking
or of poor quality. More studies are needed to test the
effectiveness of on-site syphilis testing and treatment and
its impact on perinatal outcomes, as this strategy appears
to improve compliance with treatment. Additionally,
given interactions between syphilis and HIV co-infections,
current testing and treatment guidelines may be inappro-
priate for individuals co-infected with HIV [120].
Antibiotics and antisepsis for urinary and reproductive 
tract infections (bacterial vaginosis, asymptomatic 
bacteriuria, and Group B streptococcus)
Background
Maternal genital tract infection or colonisation by patho-
genic organisms predisposes women to maternal and
perinatal mortality and morbidity. Antibiotics and anti-
septic agents have applications during pregnancy to pre-
vent and treat reproductive tract infections, particularly
presumptively for suspected or proven bacterial vaginosis
(BV) and treatment of asymptomatic bacteriuria, as well
as during the intrapartum period for Group B streptococ-
cus (GBS) colonisation to prevent perinatal infection.
Bacterial vaginosis, an imbalance of normal vaginal flora
with an overgrowth of anaerobic bacteria and a lack of
normal lactobacillary flora, has been associated with poor
perinatal outcome, particularly pre-term birth. Docu-
mented prevalence in pregnant women is common, rang-
ing from 14% to 21% in Western countries; studies from
Asian countries have reported prevalence ranges from
13.6–18% [131]. Asymptomatic bacteriuria, generally
defined as true bacteriuria in the absence of specific symp-
toms of acute urinary tract infection (UTI), occurs in 2%
to 10% of all pregnancies in high-income countries [132].
There is considerable evidence that bacteriuria and occult
UTIs are more common in low-/middle-income coun-
tries, though estimates of prevalence are prone to wide
margins of error. A urinalysis study from rural Tanzania
using a variety of diagnostic methods found that 40% of
nitrite tests and 65% of leukocyte esterase tests were posi-
tive at the first antenatal visit [133]. One study reported
significant bacteriuria in 86.6% of samples in an antenatal
population in rural Nigeria, [134,133]; other African stud-
ies have reported prevalences of bacteriuria in similar
populations of 10–24% [135-137]. Some evidence from
low- and middle-income countries that suggests that UTIs
may be frequently missed, misdiagnosed, or improperly
treated pharmacologically in these settings [138]. Asymp-
tomatic bacteriuria can lead to symptomatic UTIs, mater-
nal pyelonephritis and septicemia, and is associated with
higher rates of pre-term rupture of membranes (PROM)
and chorioamnionitis.
Maternal colonisation with GBS infection is a recognised
risk factor for neonatal colonisation and sepsis. GBS-colo-
nised women who experience either a long duration of
membrane rupture, premature delivery or intrapartum
fever are at particularly high risk for transmitting GBS to
their infants. Prevalence of colonisation with GBS is
closely associated with socioeconomic status and is simi-
lar in both pregnant and non-pregnant women [132,139].
Literature-based evidence
We identified four Cochrane reviews, one other review,
and 2 observational studies (Table 12). King et al. [140]
conducted a Cochrane meta-analysis (N = 11 RCTs, N =
7428 women), including the ORACLE study, of the effect
of maternal antibiotics in pre-term labour with intact
membranes (Additional file 18). The Cochrane meta-
analysis found that prophylactic antibiotics reduced rates
of maternal infection (RR = 0.74, 95% CI: 0.64–0.87) but
had no impact on PMR (RR = 1.22, 95% CI: 0.88–1.70)
[LOE: 1++]. In another Cochrane review, McDonald et al.
[141] compared antibiotic treatment to placebo/no treat-BMC Pregnancy and Childbirth 2009, 9(Suppl 1):S4 http://www.biomedcentral.com/1471-2393/9/S1/S4
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ment in cases of BV or intermediate vaginal flora, as well
as comparisons between two or more antibiotic regimens
(N = 15 RCTs, N = 5888 women) (Additional file 19).
Antibiotic therapy effectively eradicated BV (OR = 0.17,
95% CI: 0.15–0.20; 10 RCTs, N = 4357 women), but did
not reduce rates of pre-term premature rupture of mem-
branes (PPROM) (OR = 0.88, 95% CI: 0.61–1.28; 4 RCTs,
N = 2579 women). Antibiotics did not reduce the risk of
pre-term birth before 37 weeks (OR = 0.91, 95% CI: 0.78–
1.06; 15 RCTs, N = 5888 women), unless treatment was
administered prior to 20 weeks' gestation (OR = 0.63,
95% CI: 0.48–0.84; 5 RCTs, N = 2387 women) or women
had confirmed intermediate flora or BV (OR = 0.51, 95%
CI: 0.32–0.81; 2 RCTs, N = 894 women). In women with
previous pre-term birth, treatment did not affect the risk
of subsequent pre-term birth (OR = 0.83, 95% CI: 0.59–
1.17, 5 RCTs, N = 622 women). The three studies assessing
the impact of metronidazole treatment for BV on perina-
tal mortality found no significant impact (OR = 0.96, 95%
CI: 0.53–1.73) [LOE: 1++]
A Cochrane review by Lumbiganon et al. [142] found that
vaginal chlorhexidine washing had no effect on perinatal
mortality (RR = 1.00, 95% CI: 0.17–5.79) due to maternal
and neonatal infections (excluding GBS and HIV) com-
pared to placebo [LOE: 1++] (Additional file 20). A sys-
tematic review by Goldenberg et al. [143] of the use of
vaginal chlorhexidine treatment included two large, non-
randomised, non-blinded trials from low-/middle-
income countries that reported neonatal outcomes [LOE:
2+] (Additional file 21). One quasi-experimental trial (N
= 6965 women) included in this review from Malawi by
Taha et al. [144], found that 0.25% chlorhexidine wipes at
each vaginal examination during labour, followed by a
neonatal wipe of the same concentration soon after birth,
was associated with significant reductions in early neona-
tal deaths (29/1000 vs 37/1000 in intervention vs. control
groups, respectively, RR = 0.78) and neonatal mortality
due to infections (OR = 0.5, CI 0.29–0.88, 2.4 versus 7.3
per 1000, P < 0.005). A trial in Egypt included in the Gold-
enberg review using an almost identical study design and
treatment plan as the Malawi study [145] (N = 4415
women), found significant decreases in infant death (2.8
vs. 4.2% in intervention vs. control groups, respectively, P
= 0.01), and infant death due to infection (0.22% vs.
0.84% in intervention vs. control groups, respectively, P =
0.004). Neither study reported intrapartum stillbirth
rates, which chlorhexidine treatment could theoretically
impact by reducing infectious causes.
Thinkhamrop et al. [146] conducted a Cochrane review of
the effects of prophylactic antibiotic administration in the
second and third trimester (N = 6 RCTs, N = 2184
women) (Additional file 22). Antibiotic prophylaxis
clearly reduced the risk of PROM (OR = 0.32, 95% CI:
0.14–0.73). Among women with a previous pre-term
birth, antibiotics were associated with reduced odds of
LBW (OR = 0.48, 95% CI: 0.27–0.84), as well as pre-term
delivery (OR = 0.48, 95% CI: 0.28–0.81) in the subgroup
of women with BV. Women with previous pre-term birth
but without BV had no reduction in odds of pre-term birth
(OR = 1.06, 95% CI: 0.68–1.64). The 3 trials that reported
PMR yielded only non-significant effects (OR = 0.52, 95%
CI: 0.16–1.71). [LOE: 1++].
Conclusion
The evidence to date does not suggest any benefit in
screening and treating all pregnant women for asympto-
matic BV to prevent pre-term birth (Grade D evidence);
however, there is limited evidence that treatment with
antibiotics early in pregnancy, particularly for women
with confirmed intermediate flora or BV, may reduce pre-
term births. The results of treatment trials for pregnant
women with BV have been mixed, ranging from an 80%
reduction to a two-fold increase in pre-term birth among
women who received treatment, despite large numbers of
women in the included trials. This heterogeneity of effect
may be attributable to differences in participants' genetic
background, diagnosis criteria, timing of treatment and
antibiotic choice.
Chlorhexidine washes have long been linked to decreased
maternal positivity for GBS [147], but this intervention
also appears effective against other organisms. There is
highly promising evidence from Egypt and Malawi to sup-
port the use of vaginal chlorhexidine washing during
labour (and of the neonate after birth) in preventing
adverse maternal and neonatal outcomes associated with
infection, including neonatal death from sepsis and over-
all neonatal mortality, but stillbirths were not reported by
studies to date. Two RCTs of maternal vaginal plus new-
born skin cleansing have just been completed in South
Africa and in Pakistan, but results of these trials have not
yet been reported.
Although it appears that antibiotic prophylaxis during the
second or third trimester of pregnancy may reduce the risk
of PROM, LBW, and transmission of infection to the
neonate in high-risk pregnant women, more data are
needed to assess the risks of routine use of antibiotics in
pregnancy and to confirm whether their use can prevent
these and other substantive adverse pregnancy outcomes.
Antibiotics for pre-term premature rupture of membranes 
(PPROM) and premature rupture of membranes (PROM) 
in high-risk pregnancies
Background
Premature rupture of membranes (PROM) is a condition
where the placental membranes rupture at term prior to
the onset of labour, which is of clinical concern if labourBMC Pregnancy and Childbirth 2009, 9(Suppl 1):S4 http://www.biomedcentral.com/1471-2393/9/S1/S4
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Table 12: Impact of antibiotics for high-risk pregnancies on stillbirth and perinatal mortality
Source Location and Type of Study Intervention Stillbirths/Perinatal 
Outcomes
Reviews and meta-analyses
King and Flenady 2002 [140] Chile, Denmark, USA, South Africa, 
UK.
Meta-analysis (Cochrane). 9 RCTs 
included.
Assessed the impact of any antibiotic 
(intervention) vs. no antibiotic 
(controls) in women in pre-term 
labour with intact membranes.
PMR: RR = 1.22 (95% CI: 0.88–
1.70) [NS]
Lumbiganon et al. 2004 [142] USA.
Meta-analysis (Cochrane). 2 RCTs 
included.
Assessed the impact of chlorhexidine 
vaginal wash (intervention) vs. 
placebo (controls) in preventing 
maternal and neonatal infections 
including chorioamnionitis and sepsis.
PMR: RR = 1.00 (0.17–5.79) [NS]
Thinkhamrop et al. 2002 [146] Kenya, Belgium, USA, The 
Netherlands.
Meta-analysis (Cochrane). 3 RCTs 
included.
Assessed the impact of prophylactic 
antibiotic administration in the 
second and third trimester 
(intervention) vs. no antibiotic 
(controls), particularly in reference to 
women with prior pre-term birth and 
women with BV.
PMR: OR = 0.5 (95% CI: 0.16–
1.71) [NS]
PROM: OR = 0.32 (95% CI: 0.14–
0.73)
LBW: OR = 0.48 (95% CI: 0.27–
0.84) in women with a previous pre-
term birth
Pre-term: OR = 1.06 (95% CI: 
0.68–1.64) [NS]
Pre-term: OR = 0.48 (95% CI: 
0.28–0.81) in women with 
confirmed BV.
Goldenberg et al. 2006 [143] Malawi, Egypt.
Review. 2 non-randomised, non-
blinded trials included. N = 11,380 
women.
Assessed the impact of chlorhexidine 
vaginal wash (intervention) vs. 
placebo (controls) in preventing 
maternal and neonatal infections and 
neonatal death.
No pooled estimates given.
ENND [Malawi]: RR = 0.78
[29/1000 vs 37/1000 in 
intervention vs. control groups, 
respectively], RR = 0.78)
NM due to infections [Malawi]: 
OR = 0.5 (95% CI: 0.29–0.88, P < 
0.005)
[2.4 vs. 7.3 per 1000 in 
intervention vs. control groups, 
respectively].
Infant death [Egypt]: 2.8 vs. 4.2% 
in intervention vs. control groups, 
respectively (P = 0.01)
Infant death due to infection: 
0.22% vs. 0.84% in intervention vs. 
control groups, respectively (P = 
0.004)
McDonald et al. 2007 [141] Australia, UK, USA, South Africa.
Meta-analysis (Cochrane). 5 RCTs 
included.
Assessed the impact of oral 
antibiotics (intervention) vs. placebo/
no treatment (controls).
PMR: OR = 0.94 (95% CI: 0.52–
1.70) [NS]
Observational studies
Watson-Jones et al. 2007 [187]
.
Tanzania (Mwanza).
Prospective cohort study. Women 
(N = 1688) attending ANC.
As part of a study of the effectiveness 
of syphilis screening and treatment, 
assessed the impact of screening and 
treatment for reproductive tract 
infections (RTIs) during pregnancy on 
SB, IUGR, LBW, and pre-term birth.




SB risk factors: past history of 
stillbirth, short maternal stature 
and anaemia.
No association between treated 
RTIs and adverse pregnancy 
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does not quickly become established thereafter, as the risk
of maternal and fetal infection mounts. A related problem
is when membranes rupture prior to 37 weeks (term).
This condition precedes one-third of pre-term births, and
has proven difficult to prevent: despite socio-economic
improvements and the development of a large range of
therapeutic interventions in high-income countries, the
rate of pre-term births remains at 6 to 8 percent.
The causes of PROM and PPROM are multifactorial. Infec-
tion appears to play a major role, either as a cause or as a
consequence of PROM/PPROM. Some organisms may
produce collagenases, mucinases and proteases, which
weaken the amnion and chorion and may lead to mem-
brane rupture. Infection may also occur secondary to
membrane rupture if ascending infection leads to occult
deciduitis, intra-amniotic infection or fetal infection. A
possible mechanism for the link between infection and
pre-term delivery is bacterial stimulation of the biosynthe-
sis of prostaglandins, either directly via phospholipase A2
and C [148], or indirectly via substances such as inter-
leukin-1, tumour necrosis factor and platelet activating
factor, all of which have been identified in infected amni-
otic fluid [149].
Theoretically, antibiotic therapy could improve perinatal
outcome by two processes. Prevention or treatment of
infection may minimise maternal or fetal infectious mor-
bidity, which would have a direct impact on stillbirth inci-
dence. Secondly, in cases of PPROM, suppression of the
prostaglandin response may slow the progression to pre-
term birth described above, which could provide a win-
dow of time for fetal lung maturation and other fetal
changes that could impact incidence of complications of
prematurity.
Literature-based evidence
The literature search identified two Cochrane reviews, and
one other intervention study (Table 13). Kenyon et al.
[150] assessed the effects of administering antibiotics to
women with PROM on fetal and neonatal morbidity and
mortality, including both trials that compared antibiotic
to placebo, as well as trials without placebo (22 trials, N =
6000 women) (Additional file 23). Antibiotic administra-
tion following PROM was associated with a statistically
significant reduction in chorioamnionitis (RR = 0.57,
95% CI: 0.37–0.86), births <48 hours after membrane
rupture (RR = 0.71, 95% CI: 0.58–0.87), and births < 7
days after randomisation (RR = 0.80, 95% CI: 0.71–0.90).
There was no apparent impact on perinatal mortality or
death before discharge (13 trials; RR = 0.90, 95% CI:
0.74–1.10) [LOE: 1++].
Tita et al. 2007 [200] USA (Alabama).
RCT, subgroup analysis. Center for 
Women's Reproductive Health, 
University of Alabama at 
Birmingham. N = 241 nonpregnant 
women with reproductive tract 
infections; N = 124 conceived with 
birth outcome data (N = 59 
intervention; N = 65 controls).
Compared impact of 2 doses of 
azithromycin 1.0 g given 4 days apart 
plus sustained-release metronidazole 
750 mg daily for 7 days (intervention) 
vs. placebo (controls). Treatment was 
repeated 3x/yr until conception or 
until study termination. Reevaluation 
after randomisation with cultures and 
histopathology. Followed up 5 years.
Adverse pregnancy outcome (pre-
term birth or fetal death): 66.1% 
(39/59) vs. 61.5% (40/65) [NS] in 
intervention vs. control groups, 
respectively.
RR = 1.25 (99% CI: 0.42–3.7) 
[NS] in women colonised with 
any microbe at baseline vs. 
women without any colonisation.
[62.7% vs 50%, respectively].
RR = 0.87 (0.50–1.5) [NS] in 
women with plasma cell 
endometritis vs. women without.
[61.9% vs. 70.8%, respectively].
RR = 0.60 (95% CI = 0.3–1.2) 
[NS] in women without 
Gardnerella vaginalis colonisation 
vs. women with colonisation
RR = 0.66 (95% CI = 0.4–1.2) 
[NS] in women without Gram-
negative rod colonisation vs 
women with colonisation.
RR = 1.5 (95% CI: 1.1–2.0) in 
intervention vs. control groups, 
respectively, in the presence of 
Gardnerella vaginalis (crossover 
interaction).
RR = 1.5 (95% CI: 1.1–2.1) in 
intervention vs. control groups, 
respectively, in the presence of 
Gram-negative rod colonisation 
(crossover interaction).
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Another Cochrane review by Flenady and King [151]
examined trials that tested the impact on maternal, fetal,
and neonatal outcomes of antibiotics administered pro-
phylactically to women with PROM ≥ 36 weeks' gestation
(2 trials, N = 838 women) (Additional file 24). Antibiotic
use was significantly associated with a decreased inci-
dence of maternal infectious morbidity (chorioamnioni-
tis or endometritis) (RR = 0.43, 95% CI: 0.23–0.82), RD =
(-)4%, 95% CI: (-)7%, (-)1%), number needed to treat
[NNT] = 25, 95% CI: 14–100). The two studies reporting
perinatal outcomes showed no impact of antibiotic treat-
ment on PMR (RR = 0.98, 95% CI: 0.14–6.89) [LOE: 1+].
Conclusion
Although the two Cochrane reviews on the subject were
given a Grade B rating, they report no benefit of antibiotic
administration in cases of PROM to reduce stillbirths.
Antibiotic treatment following PPROM was associated
with a statistically significant delay in women giving birth
and reductions in major markers of neonatal morbidity
(although not perinatal mortality). This delay in delivery
would allow sufficient time for prophylactic prenatal cor-
ticosteroids to take effect. These data support the routine
use of antibiotics in this clinical situation. The increase in
the numbers of babies who developed neonatal necrotis-
ing enterocolitis with prenatal co-amoxiclav treatment
suggests that erythromycin rather than co-amoxiclav is the
antibiotic of choice in women at risk of pre-term delivery
[150]. In cases of term PROM, the Cochrane review by
Flenady and King [151] indicates that there is insufficient
evidence to justify the routine use of antibiotics prior to
the onset of labour. Although antibiotics reduced rates of
chorioamnionitis and endometritis, the low rate of mater-
nal infection in the control population (~7 percent) sug-
gests that exposure of all women with term PROM to 
antibiotics is unwarranted if treatment can be restricted to
those who develop clinical indications for antibiotic treat-
ment. Because these studies do show that antibiotics have
a statistically significant impact on chorioamnionitis,
which is a known risk factor for stillbirth, more research is
required to evaluate the potential impact of antibiotic
administration after membrane rupture.
Anti-malarials in malaria-endemic areas
Background
Globally, malaria affects almost 10% of the world's popu-
lation, and of the nearly 500 million annual cases,
approximately 1 million people die annually [152]. Par-
ticularly in areas where malaria is endemic, malaria is a
key cause of maternal illness and anaemia in pregnancy,
especially in primiparas [153,154]. Administration of
anti-malarial drugs, whether presumptively through strat-
egies such as intermittent preventive treatment (IPT) or as
Table 13: Impact of antibiotics for PPROM/PROM on stillbirth and perinatal outcomes
Source Location and Type of Study Intervention Stillbirths/Perinatal 
Outcomes
Reviews and meta-analyses
Flenady and King 2002 [151]
.
Spain.
Meta-analysis (Cochrane). 2 
RCTs included (N = 838 
women).
Compared the impact of any antibiotic 
(intervention) vs. no antibiotic (controls) in 
cases of PROM ≥ 36 wks' gestation.
PMR: RR = 0.98 (95% CI: 0.14 – 
6.89) [NS]
[2/426 vs. 2/412 in intervention 
vs. control groups, respectively].
Kenyon et al. 2003 [150] Mozambique, Norway, Sweden, 
USA, Spain, UK, Finland, Chile, 
Denmark.
Meta-analysis (Cochrane). 19 
RCTs included (N = 6411).
Compared the impact of any antibiotic 
(intervention) vs. placebo (controls) in cases 
of PPROM.
PMR/death before hospital 
discharge: RR = 0.90 (95% CI: 
0.74–1.10) [NS] [data from 13 
RCTs].
[281/4374 vs. 148/2037 in 
intervention vs. control groups, 
respectively].
Intervention studies
Kenyon et al. 2002 [201] UK and other international 
sites. Multicentre.
RCT. Pregnant women (N = 
4826) with PPROM.
Assessed the effects of co-amoxiclav and 
erythromycin singly and in combination: 325 
mg co-amoxiclav plus 250 mg erythromycin 
(group 1), co-amoxiclav plus erythromycin 
placebo (group 2), erythromycin plus co-
amoxiclav placebo (group 3), or co-
amoxiclav placebo plus erythromycin placebo 
(group 4). Antibiotics given 4× daily for 10 d 
or until delivery.
NMR: 5.2% vs. 5.7% vs. 6.2% in 
erythromycin (group 3), co-
amoxiclav (group 2) and placebo 
(group 4), respectively.
Major neonatal cerebral 
abnormality lower with 
erythromycin vs. placebo or co-
amoxiclav.BMC Pregnancy and Childbirth 2009, 9(Suppl 1):S4 http://www.biomedcentral.com/1471-2393/9/S1/S4
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treatment for diagnosed parasitemia in pregnancy, is gen-
erally recommended in areas endemic for malaria.
Literature-based evidence
The literature review identified one Cochrane review com-
prised of nine RCTs, as well as two other intervention and
observational studies (Table 14). In the Cochrane review
(N = 16 RCTs, N = 12,638 women), Garner and Gülme-
zoglu [155] found that anti-malarials reduced antenatal
parasitemia when given to all pregnant women, but had
no impact on PMR (RR = 1.02, 95% CI: 0.73–1.43, 4
RCTs, N = 2890 participants) or stillbirths specifically (RR
= 1.51, 95% CI: 0.80–2.84) (Additional file 25). However,
among women in their first or second pregnancy, a strat-
egy of IPT reduced the risk of perinatal mortality (RR =
0.73, 95% CI: 0.53–0.99; 1 RCT, N = 1986 participants)
but not stillbirth (RR = 0.87, 95% CI: 0.62–1.21, N = 3454
participants) [LOE: 1+].
An additional double-blind, placebo-controlled RCT not
included in the reviews on malaria treatment during preg-
nancy in endemic areas was conducted by Hamer et al.
[156] in which HIV-positive mothers were randomised in
blocks of 20 to one of two dosing schedules: one treat-
ment course of sulfadoxine-pyrimethamine (SP) per
month; or one course of SP per trimester. There were
slightly more stillbirths among the group receiving
monthly SP compared to the once-per-trimester group,
but this difference was not significant (2/191 vs. 5/203
total deliveries; RR = 0.43, 95% CI: 0.1–2.2) [LOE: 1+].
Conclusion
Prophylaxis with a variety of anti-malarial drugs or IPT
with SP in women having their first or second baby is
associated with a 38% lower incidence of severe anaemia
and 27% fewer perinatal deaths, according to the
Cochrane review on IPT and chemoprophylaxis [155]
(Grade B evidence). There was no obvious impact on
anaemia or perinatal outcomes when prophylaxis or IPT
was given to all women regardless of the number of previ-
ous pregnancies. Malaria parasitaemia in the blood or the
placenta is also less common with prophylaxis or IPT.
This evidence relates to a reasonable number of good
quality studies although the data show no significant evi-
dence of direct impact on stillbirths, largely owing to the
studies being underpowered to detect differences. How-
ever, the myriad maternal and perinatal benefits observed
justify the use of malaria chemoprophylaxis in women of
low parity in malaria endemic regions. SP is currently the
first-line drug for IPT in many countries according to the
WHO Treatment Guidelines [157], but patterns of drug
resistance are emerging rapidly. Although the WHO
guidelines now recommend artesunate for most para-
sitemias, many new treatment drugs and regimens are
available for the treatment of malaria; however, little
Table 14: Impact of anti-malarials in pregnancy in malaria-endemic areas on stillbirth and perinatal mortality
Source Location and Type of Study Intervention Stillbirths/Perinatal Outcomes
Reviews and meta-analyses
Garner et al. 2006 [155] Burkina Faso, Cameroon, Gambia, 
Nigeria, Uganda, Thailand, Kenya.
Meta-analysis (Cochrane). 9 RCTs 
included.
Assessed 1) the impact of treating malaria 
with any anti-malarial drug (intervention #1) 
vs. no drug (control #1), and 2) preventing 
malaria with any anti-malarial drug 
(intervention #2) vs. no drug (control #2).
PMR (treatment): RR = 1.02 (95% 
CI: 0.73–1.43) [NS] in intervention 
group #1 vs. control group #1, 
respectively.
PMR (prevention): RR = 0.73 (95% 
CI: 0.53–0.99) in intervention group 
#2 vs. control group #2, 
respectively.
Intervention studies
Hamer et al. 2007 [156] Zambia (Ndola), urban setting.
Cluster RCT. N = 456 HIV-
positive mothers (N = 224 
intervention group, N = 232 
controls).
Compared 2 dosing schedules for malaria 
prevention: 1 treatment course of SP per 
month (intervention) vs. 1 course of SP per 
trimester (controls).
SBR: RR = 0.43 (95% CI:
0.1–2.2) [NS]
[2/191 vs. 5/203 in intervention vs. 
control groups, respectively.]
Observational studies
Verhoeff et al. 1999 [202] Malawi (Chikwawa district), rural 
setting.
Prospective cohort study. N = 
1523 women.
Assessed the impact of antenatal screening 
and treatment for malaria and anaemia.
SBR: 3.7%
ENND (< 48 h postpartum): 1.7%BMC Pregnancy and Childbirth 2009, 9(Suppl 1):S4 http://www.biomedcentral.com/1471-2393/9/S1/S4
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information is available about their pharmacokinetics,
safety, and effectiveness in pregnant women, as trials have
excluded these women for fear of embryotoxicity [158].
More research is underway to expand the arsenal of anti-
malarial drugs, potentially to include other artemisinin-
based treatments than artesunate, which are also safe to
use in pregnancy [159].
Use of insecticide-treated nets (ITNs) during pregnancy
Background
Every year, an estimated 50 million pregnant women are
exposed to malaria. Pregnancy renders women more sus-
ceptible to malaria, and both the mother and fetus are at
risk of adverse consequences of malarial infection, includ-
ing maternal death from malaria, maternal anaemia and
LBW in the fetus [160]. Although the use of insecticide-
treated nets (ITNs) during pregnancy has been touted as a
key strategy for preventing malaria in pregnancy, the evi-
dence of benefit has been mixed [161]. The use of ITNs is
known to decrease maternal and placental parasitemia,
and raise haemoglobin concentrations in women with
their first to fourth pregnancies [161]. ITNs are recom-
mended by the WHO in conjunction with IPT and case
management of malarial infection [162] to prevent
malaria in pregnant women living in malaria-endemic
areas of Africa and Asia.
Literature-based evidence
One systematic review, published in two journals and
comprised of 5 RCTs, was identified in our literature
search (Table 15). This review by Gamble et al. [161]
assessed ITN use during pregnancy (N = 5 RCTs, with clus-
ter- and individual-randomised designs) (Additional file
26). Four trials from sub-Saharan Africa compared the use
of ITNs with no nets, and one trial from Asia compared
ITNs with untreated nets. In Africa, ITNs reduced placen-
tal malaria in all pregnancies compared with no nets (RR
= 0.79, 95% CI: 0.63–0.98). The use of ITNs also reduced
LBW incidence (RR = 0.77, 95% CI: 0.61–0.98) and fetal
loss (miscarriages plus stillbirths) in the first to fourth
pregnancy (RR = 0.67, 95% CI: 0.47–0.97), but not in
fifth and higher-order pregnancies. ITNs also appeared to
have a beneficial impact on anaemia and clinical malaria
but these trends were not statistically significant [LOE:
1++]. The updated systematic review by the same author
in 2007 mentions four trials in which stillbirth outcomes
are reported (Additional file 26). Summary estimates for
the effect of ITN use were estimated from 3 studies [163-
165] reporting fetal death (miscarriage plus stillbirths).
ITNs compared to no nets reduced fetal death (by 33%
(RR = 0.67, 95% CI: 0.47–0.97) in the first or second preg-
nancy [LOE: 1++].
Conclusion
The available studies and Cochrane review provide strong
evidence of benefit of ITN use in pregnancy (Grade A evi-
dence). ITNs significantly decreased maternal and placen-
tal parasitaemia, increased mean birth weight in most
trials, and reduced rates of fetal loss and other negative
pregnancy outcomes in women in their first or second
Table 15: Impact of ITNs on stillbirth and perinatal mortality
Source Location and Type of Study Intervention Stillbirths/Perinatal 
Outcomes
Reviews and meta-analyses
Gamble et al. 2006 Gamble et al. 
2007 [161,203]
Kenya.
Meta-analysis (Cochrane). 5 RCTs 
included.
To compare the impact of ITNs 
(permethrin 500 g/m2 except in 
one trial that used cyfluthrin; 
intervention) vs. untreated nets or 
no nets (control) in preventing 
malaria in pregnancy. All African 
trials gave double- or family-sized 
nets to each household, vs. single-
sized nets in Thailand.
Fetal death (3 RCTs):
RR = 0.68 (95% CI: 0.48–0.98, P = 
0.04) in all gravidae
RR = 0.67 (95% CI: 0.47–0.97, P = 
0.03) in low gravidae (1–2 
pregnancies)
RR = 1.02 (95% CI: 0.17–6.23, P = 
0.98) [NS] in high gravidae (> 4 
pregnancies)
Birth weight: Mean increase: 50 g 
(95% CI: 20–90 g) in women with 
1–2 prior pregnancies.
LBW (1 RCT): RR = 0.77, 95% CI: 
0.61–0.98) in women with 1–2 
prior pregnancies
Placental malaria: RR = 0.79, 95% 
CI: 0.63–0.98).
Fetal death (with untreated nets as 
control group, 1 RCT): RR = 0.21 
(95% CI: 0.05–0.92) in all gravidae
[2/102 vs. 10/97 in intervention vs. 
control groups, respectively.]BMC Pregnancy and Childbirth 2009, 9(Suppl 1):S4 http://www.biomedcentral.com/1471-2393/9/S1/S4
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pregnancy, with some benefit likely through the fourth
pregnancy. Thus, ITNs are recommended for pregnant
women, particularly primigravidae, in malaria-endemic
areas. As four of the five trials considered were conducted
in Africa, and the only trial conducted in Asia compared
ITNs with untreated nets on the Thai-Burmese border, fur-
ther efficacy studies of ITNs to prevent malaria in preg-
nancy are recommended in areas with less intense (as well
as Plasmodium vivax) transmission in Asia and Latin Amer-
ica.
Prevention of mother-to-child transmission of HIV
Background
High maternal viral load, which measures the level of HIV
RNA in the plasma, is a strong independent risk factor for
vertical (mother-to-child) transmission of HIV. In addi-
tion, breastfeeding, young maternal age, other STDs,
advanced maternal HIV disease, low CD4 cell count, cho-
rioamnionitis, prolonged rupture of membranes, vaginal
delivery and associated events increasing maternal bleed-
ing, and history of stillbirth also increase the risk of verti-
cal transmission [166]. Anti-retroviral (ARV) drugs,
primarily zidovudine, nevirapine, or a combination of the
two, are recommended during pregnancy to reduce
mother-to-child transmission of HIV because by reducing
viral replication, they effectively reduce maternal viral
load. Additionally, the drugs provide some measure of
pre-exposure prophylaxis for the fetus because they cross
the placenta, and can be administered directly to the baby
after delivery (usually within 72 hours of birth) as post-
exposure prophylaxis. In developed countries, rates are
around 1–2% thanks to the availability of highly active
ARV therapy (HAART) [166]. HAART availability remains
limited in low and middle-income countries, but simpler
and less expensive ARVs are now widely available. While
numerous studies have been conducted on the efficacy of
ARVs for PMTCT, few have reported stillbirth outcomes.
Literature-based evidence
We identified three systematic reviews (3 reviews and
meta-analyses comprised of 18 RCTs) and 8 other studies
(Table 16). The studies assessed a range of different ARV
drug choices, dosages, and timing of administration to
mother, infant, or both. In a Cochrane review by Volmink
et al. comparing ARVs administered to mothers and their
infants to placebo [166], all 6 eligible RCTs reported sta-
tistically non-significant reductions in stillbirths (results
were not pooled: see Table 16 for RRs and CIs) (Addi-
tional file 27). Comparing longer vs. shorter ARV regi-
mens, 3 RCTs showed statistically non-significant
reductions in stillbirths for longer regimens (results were
not pooled, see Table 16 for RRs and CIs) [LOE: 1++].
Another systematic review by Suksomboon et al. [167]
supported the efficacy of zidovudine to prevent vertical
HIV transmission (RR = 0.57, 95% CI: 0.45–0.71 in zido-
vudine vs. placebo groups, respectively) as well as to
reduce LBW (Pooled RR = 0.75, 95% CI: 0.57–0.99, P =
0.039), but found no significant effects of zidovudine on
stillbirth or pre-term delivery (Additional file 28). The
Suksomboon et al. review also found no differences
between short-long and long-long regimens of zidovu-
dine therapy in rates of perinatal HIV transmission, infant
death, stillbirth, or pre-term birth. However, in the African
studies in this review, zidovudine plus lamivudine combi-
nation therapy was very effective in preventing vertical
transmission (adj. OR = 0.23, P < 0.0001). One included
trial found that 2-dose nevirapine prophylaxis (intrapar-
tum plus newborn dose, given in combination with zido-
vudine) reduced the death rate of live-born babies by 80%
(RR = 0.20, 95% CI: 0.05–0.90) versus nevirapine placebo
plus zidovudine; however, this regimen had no impact on
SBR (RR = 1.11, 95% CI: 0.48–2.56) [LOE: 1++].
Similarly, comparing HIV-1-infected pregnant women
given monotherapy, combination therapy without pro-
tease inhibitors, and combination therapy with protease
inhibitors to women who did not receive ARVs, Tuomala
et al. [168] reported similar SBRs between all groups
[LOE: 2+]. Efavirenz therapy also appears to be ineffective
in preventing stillbirths; in a comparison of 6 treatment
regimens, 3 of which contained efavirenz, Bussmann et al.
[169] reported no impact of efavirenz on SBR (P = 0.7)
[LOE: 1-].
HAART, the administration strategy of choice for HIV dis-
ease where available, is associated with improved mater-
nal and infant outcomes, but does not appear to impact
stillbirth incidence. Townsend et al. [170] compared
women on HAART with women on mono/dual therapy.
In comparison with exposure to mono/dual therapy,
exposure to HAART was associated with a non-significant
increased risk of stillbirth (adj. OR = 2.27, 95% CI: 0.96–
5.41; P = 0.063) [LOE 2+]; this trend was not observed by
Tonwe-Gold et al. [171], who found that compared to
women on short-course anti-retroviral (scARV) PMTCT
regimens, women on HAART had no difference in SBR (P
= 1.00) [LOE: 2+]. Sharma et al. [172] found that the total
live birth rate increased by 150% (P = 0.001) in HIV-pos-
itive women given HAART compared to the pre-HAART
era, compared with a mere 5% increase during the same
time period in HIV uninfected women, but the study
design was unable to determine stillbirth rates before or
during HAART administration [LOE: 3].
A third PMTCT-related Cochrane review by Wiysonge et
al. [173] reviewed the potential for vitamin A supplemen-
tation to reduce vertical transmission of HIV infection (4
RCTs, N = 3033 HIV-positive pregnant women), but
found no evidence of impact of vitamin A supplementa-BMC Pregnancy and Childbirth 2009, 9(Suppl 1):S4 http://www.biomedcentral.com/1471-2393/9/S1/S4
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Table 16: Impact of PMTCT on stillbirth and perinatal mortality
Source Location and Type of Trial Intervention Stillbirths/Perinatal Outcomes
Reviews and meta-analyses
Suksomboon et al. 2007 [167] USA, France, Côte d'Ivoire, Burkina 
Faso, Thailand, Bahamas, Brazil.
Meta-analysis (Cochrane). 15 trials, 
5 reporting SBR.
Assessed a variety of regimens and 
dosing schedules for PMTCT for 
efficacy in preventing vertical 
transmission, infant death, and 
adverse pregnancy outcomes.
Zidovudine vs. placebo: 
Vertical transmission: Pooled RR = 
0.57 (95% CI: 0.45–0.71)
LBW: Pooled RR = 0.75 (95% CI: 




nevirapine therapy vs. nevirapine 
placebo (both given zidovudine) 
[1 RCT]:
Infant death: RR = 0.20 (95% CI: 
0.05–0.90)
SBR: RR = 1.11 (95% CI: 0.48–2.56) 
[NS]
[10/826 vs.9/835 in intervention vs. 
control groups, respectively 
(pooled)].
Volmink et al. 2007 [166] Thailand, Côte d'Ivoire, Burkina 
Faso, Uganda, Kenya, USA, France, 
Brazil, Bahamas, Tanzania, 
Zimbabwe.
Meta-analysis (Cochrane). 13 RCTs 
included that reported stillbirth 
rates.
Assessed the impact of zidovudine 
alone (intervention #1), nevirapine 
alone (intervention #2), and 
combination zidovudine-nevirapine 
therapy (intervention #3) vs. placebo 
(controls) on MTCT. Subgroups also 
analyzed according to breastfeeding.
Pooled analysis not given for SBR.
ARV vs. placebo:
Vertical transmission: RR = 0.46 
(95% CI: 0.35–0.60)
SBR: RR = 0.14 (95% CI: 0.02–1.17); 
RR = 0.33 (95% CI: 0.01–8.11); RR 
= 0.40 (95% CI: 0.07–2.15); RR = 
0.80 (95% CI: 0.20–3.18); RR = 3.02 
(95% CI: 0.12–73.57); RR = 3.50 
(95% CI: 0.74–16.55) for the 6 
trials, respectively.
Long vs. short-course zidovudine:
SBR: RR = 0.25, 95% CI: 0.05–1.17; 
RR = 0.33, 95% CI: 0.11–1.01; RR = 
0.55, 95% CI: 0.23–1.33, for the 3 
trials, respectively
Wiysonge et al. 2005 [173] Tanzania, Zimbabwe, South Africa, 
and Malawi.
Meta-analysis (Cochrane). 4 RCTs 
included (N = 2855 participants).
Assessed the impact of vitamin A 
supplementation (intervention) vs. 
placebo (controls) on MTCT.
SBR: OR = 0.99 (95% CI: 0.67–1.46) 
[NS]
Intervention studies
Bussmann et al. 2007 [169] Botswana.
RCT.
Assessed the impact of 6 HAART 
regimens, 3 of which contained 
efavirenz (intervention), vs. non-
efavirenz regimens (controls).
SBR: No difference between 
efavirenz and non-efavirenz-
exposed pregnancies (P = 0.7).
Sharma et al. 2007 [172] USA (New York).
Prospective cohort study (before-
after design). Women's Interagency 
HIV study, data collected pre-
HAART (1994–95) and during 
HAART (2001–02).
Assessed the impact of HAART on 
live birth rates among HIV-positive 
women (intervention) compared to 
HIV-negative women (comparison).
Live birth rate: 150% vs. 5% higher 
in intervention vs. comparison 
groups after introduction of 
HAART (P = 0.001).BMC Pregnancy and Childbirth 2009, 9(Suppl 1):S4 http://www.biomedcentral.com/1471-2393/9/S1/S4
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tion on stillbirths (OR = 0.99, 95% CI: 0.67–1.46) [LOE:
1++] (Additional file 29).
Conclusion
Overall, while there is no consensus on the ideal regimen
for preventing vertical transmission, there is considerable
evidence that in resource-poor settings, zidovudine alone
or in combination with other ARVs such as lamivudine or
nevirapine reduces the risk of vertical transmission and
infant death, as well as positively impacts birth weight
(overall Grade C evidence). In mothers already receiving
zidovudine prophylaxis, a single dose of nevirapine to
mothers during labour and to infants after birth further
decreases the risk of vertical transmission and infant
death. Wherever available, HAART appears to be associ-
ated with statistically significant improvement in live
birth rate. However, there is no evidence that any regimen
of PMTCT impacts stillbirth incidence. Additionally, there
is no evidence for any impact of vitamin A supplementa-
tion on stillbirths in HIV-positive mothers. As PMTCT reg-
imens are of clear benefit to maternal health (when
administered to pregnant women) and infants (when
administered during pregnancy and the postnatal period),
we recommend their inclusion in ANC programs based
Sperling et al. 1996 [204] USA.
RCT. Mother-infant pairs (N = 
402).
Compared the impact of maternal 
zidovudine treatment (intervention) 
vs. placebo (controls).
Rate of HIV-1 transmission: 7.6% 
(95% CI: 4.3–12.3%) vs. 22.6% (95% 
CI: 17.0–29.0%) in intervention vs. 
control groups, respectively (P < 
0.001).
Transmission occurred at a wide 
range of maternal plasma HIV-1 
RNA levels.
No SBR reported.
Stiehm et al. 1999 [205] USA, Puerto Rico.
RCT. Women (N = 501) at 53 
centers.
Assessed the impact of HIV 
immunoglobulin 200 mg/kg IV 
infusion every 4 wks beginning 
between 20 – 30 wks gestation and 
during delivery plus 200 mg/kg IV 
infusion to baby within 12 hours of 
birth, plus maternal+infant 
zidovudine standard course 
(intervention)
vs. standard polyvalent HIV 
antibody-negative IVIG to mother 
and baby as above, plus 
maternal+infant zidovudine standard 
course (controls).
SBR: RR = 0.33 (95% CI: 0.01–8.03) 
[NS]
[0/231 vs. 1/228 in intervention vs. 
control groups, respectively.]
Tonwe-Gold et al. 2007 [171] Cote d'Ivoire (Abidjan).
Observational cohort study.
Assessed the impact of HAART vs. 
short-course anti-retroviral (scARV) 
PMTCT regimens to which women 
were allocated according to their 
clinical and immunological status.
SBR: [NS]
[4 (3.9%) vs. 6 (4.3%) in HAART vs. 
scARV for PMTCT groups, 
respectively (P = 1.00)].
Townsend et al. 2007 [170] UK, Ireland.
Retrospective study. Pregnancies in 
women notified to the National 
Study of HIV in Pregnancy and 
Childhood (NSHPC).
Compared women on HAART 
(intervention) to women on mono/
dual therapy (controls).
SBR: adj. OR = 2.27 (95% CI: 0.96–
5.41; P = 0.063) [NS]
[12.7/1000 births (43/3384) vs. 5.7/
1000 (6/1061) in HAART vs. mono/
dual therapy groups].
Tuomala et al. 2002 [168] USA (Miami, Florida & Southern 
California).
Case control study. 2 multisite 
studies + 3 single site studies.
Compared impact of combination 
ART (cases) vs. no ART (controls)
SBR: 12/2123 (1%) vs.7/1143 (1%) in 
intervention vs. control groups, 
respectively. Adjusted rate (for 
CD4, tobacco, alcohol, illicit drug 
use): 1% (P = 0.92) [NS]
Onah et al. 2007 [206] Nigeria (Enugu).
Retrospective case-control study. 
Pregnant women (N = 162; N = 62 
HIV-positive women, N = 100 HIV-
negative controls) delivering in the 
University of Nigeria Teaching 
Hospital from 2002–2004.
Compared incidence of stillbirth in 
untreated HIV-positive women 
(cases) vs. HIV-negative women 
(controls).
SBR: No difference (P > 0.05).
4.8/1000 vs. 1.0/1000 in cases vs. 
controls, respectively.
Maternal and fetal morbidities: 
higher in HIV-positive group.
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on these benefits alone, with the caveat that there is no
evidence of their efficacy in preventing stillbirths.
Periodontal care during pregnancy
Background
Periodontal disease, including gingivitis and periodonti-
tis, is one of the most common chronic disorders of infec-
tious origin known in humans, with a reported prevalence
varying between 10 and 60% in adults, depending on
diagnostic criteria. Periodontal disease is initiated by over-
growth of certain bacterial species, with a majority of
Gram-negative, anaerobic bacteria growing in subgingival
sites and producing lipopolysaccharide (LPS) endotoxins
and other bacterial substances. The host response to peri-
odontal pathogens causes persistent inflammation with
high levels of proinflammatory cytokines, contributing
locally to periodontal disease as well as to systemic effects
including increased risk of atherosclerosis, myocardial
infarction, stroke, diabetes mellitus. Several studies have
highlighted the relationship between maternal periodon-
tal disease and birth outcomes, including prematurity
[174,175]. A large number of studies have explored the
mechanisms by which periodontal disease might impact
LBW, miscarriage, and pre-eclampsia [176]. Most of these
studies have centered on prematurity, and although sev-
eral RCTs have reported an association between periodon-
tal care and reduced rates of pre-term birth or pre-term
LBW, systematic reviews and meta-analyses on the subject
have been unable to determine conclusively whether there
are any associations with these outcomes [177]. There has
been much less attention to date as to whether periodon-
tal care could prevent stillbirth.
Literature-based evidence
Our literature search identified 2 systematic reviews, and
4 other observational/intervention studies, that reported
stillbirth or perinatal mortality outcomes (Table 17).
None of the systematic reviews reported a conclusive asso-
ciation between periodontal disease and stillbirth or peri-
natal mortality. In a systematic review by Xiong et al.
[176], only one cohort study [178] reported stillbirth or
miscarriage as an outcome. Regression analysis revealed
no significant relationships between the severity of perio-
dontal disease and pre-term birth or LBW, but did eluci-
date a significant correlation between poorer periodontal
health and those that experienced a late miscarriage (adj.
OR = 2.54, 95% CI: 1.20–5.39) (Additional file 30). An
update of this analysis [179] which included 2 studies
reported an effect size ranging from 2.54–3.84 times
increased risk of fetal loss attributable to periodontal dis-
ease (Additional file 31). Tarannum et al. [180] also
reported a convincing link between periodontal disease
and adverse pregnancy outcome (OR = 5.5, 95% CI: 1.4–
21.2; P = 0.014). A more recent prospective cohort study
from Pakistan [181] involving a periodontal examination
at 20–26 weeks' gestation for study subjects (N = 1152
women) found that 76% of participants had moderate to
severe periodontal disease. Stillbirth rates tended to be
higher in the fourth quartile versus the first quartile of
severity of periodontal disease (for stillbirth: 19/1000 vs.
41/1000 in 1st vs. 4th quartiles, respectively, P = 0.069).
The same was true for perinatal and neonatal mortality
rates. While some evidence supported an association
between periodontal disease and early pre-term birth, the
association was not statistically significant. Late pre-term
birth and LBW were not associated with measures of peri-
odontal disease.
While published data convincingly demonstrate a linkage
between periodontal disease and stillbirth incidence, the
limited literature on interventions for periodontal disease
has not yet shown any evidence of impact on pre-term
birth or perinatal mortality. An RCT by Macones et al.
[182], which provided scaling and root planing to an
intervention group versus tooth polishing for controls,
reported no impact of periodontal disease treatment on
pre-term birth rate at less than 35 weeks gestation (RR =
1.55, 95% CI: 0.90–2.67), and no difference in rates of the
composite outcome of major neonatal mortality or mor-
bidity between the intervention and control groups (RR =
1.30, 95% CI: 0.83–2.03) [183]. In a competing-risks
analysis by Michalowicz et al. [184], neither the risk of
pre-term birth (P = 0.51) nor of spontaneous abortion or
stillbirth (P = 0.08) differed significantly between women
who were given periodontal care (scaling and root plan-
ing) at 21 weeks' gestation versus women whose care was
delayed until after they gave birth.
Conclusion
There appears to be a relatively consistent association
between periodontal disease and risk of adverse preg-
nancy outcome in some populations [174]. Many studies
have explored the potential association of periodontal
disease and periodontal care with pre-term birth or pre-
term LBW, but the evidence is conflicting. The observa-
tional studies that reported statistically significant results
lack the design strength to eliminate confounding and
definitively attribute causation. Variability in definition of
periodontal disease, as well as design flaws in published
studies, suggest that the available findings should be
viewed with caution (overall Grade C evidence). Very few
RCTs have assessed the impact of interventions for perio-
dontal disease on stillbirth and perinatal mortality, and
most have been designed with pre-term birth as the pri-
mary outcome and have been underpowered to detect
impact on perinatal deaths. Although clinical trial data
suggest that non-surgical periodontal treatment in the sec-
ond trimester is a safe and effective strategy to improve
periodontal indicators, there is currently insufficient evi-
dence to recommend routine periodontal care as an effec-BMC Pregnancy and Childbirth 2009, 9(Suppl 1):S4 http://www.biomedcentral.com/1471-2393/9/S1/S4
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Table 17: Impact of interventions for periodontal disease on stillbirth and perinatal mortality
Source Location and Type of Study Intervention Stillbirths/Perinatal Outcomes
Reviews and meta-analyses
Xiong et al. 2007 [179] UK.
Review. 2 cohort studies included.
Assessed the association of 
periodontal disease with fetal death.
Fetal death (miscarriage or SB): 
Effect size ranged from 2.54–3.84.
Xiong et al. 2006 [176] UK.
Review. 1 cohort study included (N 
= 3738 participants).
Assessed any association between 
periodontal disease and adverse 
pregnancy outcome.
Fetal death (Miscarriage+SB): adj 
OR = 2.54 (95% CI: 1.20–5.39)
Intervention studies
Michalowicz et al. 2006 [184] USA.
RCT. Women (N = 823 women; N 
= 413 intervention, N = 410 
controls) at 13–17 wks' gestation
Used competing-risks analysis to 
assess the impact of scaling and root 
planing before 21 wks' gestation, plus 
monthly tooth polishing and oral 
hygiene instruction (intervention) vs. 
scaling and root planing after delivery 
(controls).
SBR (20–37 wks):
[3/413 vs. 10/410 in intervention 
vs. control groups, respectively, P 
= 0.04 [NS]]
Pre-term: P = 0.51 [NS]
Fetal death (miscarriage+SB):
[5/413 vs. 14/410 in intervention 
vs. control groups, respectively, P 
= 0.08].
Macones et al. 2008 [182] USA.
RCT. Multicentre. Women (N = 
757; N = 378 intervention, N = 379 
controls) < 20 weeks' gestation with 
periodontal disease identified 
through screening.
Assessed the impact of periodontal 
care (scaling and root planing; 
intervention) vs. tooth polishing 
(controls) on pre-term birth and its 
complications.
Major neonatal morbidity/
mortality: RR = 1.30 (95% CI; 
0.83–2.03) [NS]
[10.6% vs. 8.2% in intervention vs. 
control groups, respectively]
Pre-term (< 35 wks): RR = 1.55 
(95% CI: 0.90–2.67) [NS]
[8.6% vs. 5.6% in intervention vs. 
control groups, respectively]
Observational studies
Oittinen et al. 2005 [207] Finland.
Observational study. Women who 
became pregnant (N = 130) out of a 
total cohort of women who had 
discontinued contraception in order 
to become pregnant.
Assessed the association between 
maternal disease status, including 
periodontal disease and BV, with and 
adverse pregnancy outcome.
Adverse pregnancy outcome (pre-
term birth or fetal death):
OR = 5.5 (95% CI: 1.4–21.2, P = 
0.014).
[26/130 (20%) of sample. 
Univariate analysis also showed 
significant association of 
periodontal disease with adverse 
outcome (P = 0.012)].
Fetal death (miscarriage+SB): 17/
130.
Pre-term: N = 9.
Mobeen et al. 2008 [181] Pakistan. Community setting.
Prospective cohort study. Pregnant 
women enrolled at 20–26 weeks 
gestation and given dental exam, 
then followed until delivery.
Assessed the association between 
maternal periodontal disease severity 
with adverse pregnancy outcomes.
SBR:
19/1000 vs. 41/1000 (P = 0.069) 
between the first and the fourth 
periodontal quartiles (least severe 
disease vs. most severe disease).
26/1000 vs. 42/1000 (P = 0.131 
[NS]) with increasing severity of 
the clinical attachment measures.
22/1000 vs. 50/1000 stillbirths (P = 
.033) with increasing severity of 
plaque index measures,
24/1000 vs. 51/1000 (P = 0.019) 
with increasing severity of the 
gingival index measures.BMC Pregnancy and Childbirth 2009, 9(Suppl 1):S4 http://www.biomedcentral.com/1471-2393/9/S1/S4
Page 39 of 49
(page number not for citation purposes)
tive strategy to prevent stillbirths or pre-term birth
[183,184,182]. This emerging area of research warrants
further study, however, particularly in low-/middle-
income countries. Care for periodontal disease provided
prior to pregnancy may offer more significant benefits,
but this strategy has not yet been tested.
An additional mechanism by which periodontal care
could prevent stillbirths is the emerging and clinically
important link between periodontal disease and pre-
eclampsia. A recent meta-analysis by Vergnes et al. 2008
reported that women with periodontal disease had almost
double the risk of pre-eclampsia compared with women
without periodontal disease (OR = 1.76, 95% CI: 1.43–
2.18) [185]. This linkage, if it can be confirmed, would be
particularly relevant to low-/middle-income country set-
tings given high rates of periodontal disease as well as
higher incidence of pre-eclampsia than in high-income
countries. Verifying this association and identifying the
physiological mechanisms involved will require further
studies.
Summary
While high-quality Cochrane or other published reviews
or meta-analyses were available for many interventions,
few of these reviews or their component studies reported
stillbirths specifically, and evidence from different studies
and different reviews was frequently conflicting. Addi-
tionally, comparing findings even for the same interven-
tion was often difficult due to differing study objectives
and design issues including study incommensurability,
differences in outcome definitions, and differences in
allocation technique. Even rigorous intervention trials
were usually conducted in tertiary care centres where even
controls received ANC, often of better quality than
women who do not enroll in such trials; in such trials with
appropriate care and monitoring, stillbirths are more rare
than in the general population (e.g., use of anti-hyperten-
sive agents in pregnant women with hypertension). This
bias limits generalisability of findings and further hinders
demonstration of impact attributable to an intervention.
To bridge the evidence gap, there is a need for large
research trials to report stillbirths–disaggregated from the
perinatal mortality composite measure–as an outcome
whenever feasible, and for rigorous RCTs in low-resource
settings. The recommendation of each intervention for
inclusion in programs is given in Table 18.
In many low-/middle-income countries, stillbirths associ-
ated with infection comprise a large proportion of still-
births. Preventing stillbirth associated with maternal
infection is appealing because it targets a large proportion
of the burden, and interventions and service delivery
needs are relatively straightforward, short-term, and non-
invasive compared with behavioural, surgical, or nutri-
tional interventions. While the evidence base for
prevention of stillbirths with interventions prior to or dur-
ing pregnancy is limited, evidence strongly supports a
benefit of syphilis screening and treatment and malaria
prophylaxis in endemic areas, and these interventions
should be incorporated into ANC programs where epide-
miological evidence indicates women are at risk. Some
estimates suggest that better syphilis screening and treat-
ment could prevent as many as half of all stillbirths in
areas with high syphilis prevalence [186]. When women
are treated for syphilis successfully, their risk of stillbirth
is similar to uninfected women [187]. The logistical chal-
lenges of providing syphilis screening and treatment, par-
ticularly at the community level, are many, including
training workers to perform a complex test or tests, evalu-
ating ambiguities in diagnosis, preventing test and phar-
maceutical supply stock outs, managing the occasional
penicillin sensitivity, and ensuring that clients receive
both test results and treatment. However, the high rates of
ANC attendance (one or more visits) in much of sub-
Saharan Africa and South Asia provide a potential infra-
structural framework to provide access to this important
intervention.
Given the endemicity of malaria in much of sub-Saharan
Africa and South Asia, where stillbirth rates are concomi-
tantly high, the three-pronged approach to malaria pre-
vention and treatment advocated by the WHO (ITNs, IPT,
and treatment of parasitemia with artemisinin-based ther-
apies) appears prudent, though further research is needed
about the safety of artemisinin-based drugs other than
artesunate and the impact of timing of dosage on stillbirth
rates.
Other interventions, such as anti-helminthic treatment,
showed promising impact on stillbirth rates but require
more studies to confirm effectiveness. While we recom-
mend the continued practice of PMTCT for HIV, and
malaria chemoprophylaxis in women of low parity, these
recommendations are based primarily on demonstrated
benefit for maternal or other fetal/neonatal outcomes,
rather than definitive impact on stillbirths or perinatal
mortality.
Research gaps
The area of stillbirth prevention, particularly the develop-
ment of interventions that address the multifactorial
causes of antepartum stillbirths, is a ripe area for new
research (Table 19). In this review, we found evidence that
several interventions brought about reductions in known
risk factors for stillbirth, yet failed to bring about statisti-
cally significant improvements in stillbirth rates. For
example, anti-platelet agents clearly reduced rates of PIH
and pre-eclampsia, yet no statistically significant impact
on stillbirths was noted. Similarly, antibiotic treatmentBMC Pregnancy and Childbirth 2009, 9(Suppl 1):S4 http://www.biomedcentral.com/1471-2393/9/S1/S4
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for PROM was associated with a significant reduction in
chorioamnionitis, yet yielded no statistically significant
reduction in stillbirth rates. These findings are most likely
attributable to studies underpowered to detect impact of
the intervention on stillbirth rates, but could also be due
to intervention at a point too distal in a multi-causal path-
way, a deleterious effect of the intervention itself, includ-
ing adverse effects of drugs, etc. For these interventions
and others (Table 19), further research specifically
designed to measure stillbirth as an outcome is needed.
Large gaps remain in the basic science of stillbirth causa-
tion and many of the maternal conditions and patholo-
gies that lead to stillbirth, including pathophysiological
mechanisms involved in pre-eclampsia, autoimmune and
inflammatory responses that threaten pregnancy, still-
unknown risk factors, and drug safety and efficacy studies.
Table 18: Summary of evidence grading for all interventions prior to and during pregnancy to prevent stillbirth and perinatal mortality 
reviewed in this paper
Evidence of no or 
negative impact
(leave out of programs)
Uncertain evidence
(need for additional 
research before including 
in programs)
Some evidence
(may include in programs, 
but further evaluation is 
warranted)
Clear evidence

















Syphilis screening and 
treatment
X









PMTCT for HIV X2
Periodontal care X
1Possibly effective in some low-resource settings
2Maternal and infant benefitBMC Pregnancy and Childbirth 2009, 9(Suppl 1):S4 http://www.biomedcentral.com/1471-2393/9/S1/S4
Page 41 of 49
(page number not for citation purposes)
These studies will guide development of appropriate
interventions for maternal conditions and infections asso-
ciated with stillbirth causation.
Evidence for some newly recognised risk factors for still-
birth, such as periodontal disease, suggests the need for
large, appropriately designed randomised trials to assess
whether effective interventions can be designed to mini-
mise these risks.
Conclusion
Knowledge and evidence gaps in the dynamics and pre-
vention of antepartum stillbirth are numerous and deep.
At present, there is no standard international classification
system for stillbirth causation, and disagreement persists
about the lower benchmarks of birth weight and gesta-
tional age used to define stillbirth. These ambiguities
complicate measurement of stillbirths, comparison of dif-
ferent studies measuring stillbirth, and tracking trends
over time [186]. Development of practical, standardised
templates to assess causes of stillbirth is underway, which,
if adopted internationally, will help to more accurately
measure the burden of intrapartum versus antepartum
stillbirths and their associated causes. These data are cru-
cial to inform the development of appropriate interven-
tions. Meanwhile, the numerous gaps in the growing list
of stillbirth risk factors, the pathophysiology of certain
maternal infections and conditions, and the many inter-
ventions for which there is conflicting evidence of benefit
suggest the need for greater investment in large studies
powered to measure stillbirth rate reductions. Armed with
more definitive knowledge of which interventions are
effective and prevent the most stillbirths in particular set-
tings, we can more effectively select and implement these
interventions and prevent unnecessary loss of life.
Programmatically, the clearest evidence of impact in still-
birth prevention is adequate prevention and treatment of
maternal infections such as syphilis and malaria. Given
the enormous human burden of both of these diseases in
many countries with the world's highest stillbirth rates,
effective prevention and treatment of syphilis and malaria
have the potential to greatly reduce global stillbirth rates.
Efforts prior to and during pregnancy to prevent stillbirth
will be most effective in conjunction with effective moni-
toring interventions in pregnancy, prompt recognition
and management of high-risk pregnancies and complica-
tions, and a system of interlinked facilities capable of
prompt referral to ensure that complications are capably
Table 19: Research gaps
Basic science and physiological studies
• Mechanisms of causation of hypertensive disorders of pregnancy and how these cause stillbirths*
• Auto-immune pathophysiology in stillbirth causation
• Association of periodontal disease with pre-eclampsia and pathophysiology of subsequent stillbirth*
• Dynamics of stillbirth causation in intrahepatic cholestasis
• Drug safety and efficacy studies:
 Anti-malarials in pregnancy
 Drugs for intrahepatic cholestasis
 Non-penicillin treatments for syphilis
 Antibiotic use in pregnancy
• Identification of other unknown risk factors
• Prevalence of uterine abnormalities in low-/middle-income countries
Pilot/cohort studies of interventions
• New approaches for PIH and chronic hypertension management in community settings*
• Management protocols for HIV and syphilis co-infection
• Management of penicillin drug allergy in community settings
• Diagnosis and surgical repair of uterine abnormalities in women with recurrent fetal loss
• Intravenous immunoglobulin treatment (compared to heparin, aspirin, or other anti-coagulants) in selected populations with recurrent 
pregnancy loss and antiphospholipid antibodies
Well-designed large RCTs of interventions powered to detect stillbirths 
• Periodontal care studies powered to detect impact on stillbirth rates*
• Calcium supplementation to prevent PIH and pre-eclampsia in deficient populations
• Anti-oxidant supplementation in deficient populations
• Management of intrahepatic cholestasis including nonstress test, amniotic fluid index, meconium screening and early delivery
• Calcium supplementation in high-risk pregnancies*
• Antibiotics for pPROM*
Effectiveness trials in large populations/at scale
• Maternal anti-helminthic treatment: impact on maternal anaemia and stillbirth*
• On-site syphilis testing and treatment
• ITNs for Plasmodium vivax and in lower-transmission settings (Asia and Latin America)
*Priority areasBMC Pregnancy and Childbirth 2009, 9(Suppl 1):S4 http://www.biomedcentral.com/1471-2393/9/S1/S4
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managed to prevent unnecessary loss of life for mothers or
their babies.
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